quinazolines has been researched along with bibw 2992 in 490 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (1.84) | 29.6817 |
| 2010's | 465 (94.90) | 24.3611 |
| 2020's | 16 (3.27) | 2.80 |
| Authors | Studies |
|---|---|
| Baumann, M; Dörfler, A; Eicheler, W; Hering, S; Krause, M; Schütze, C; Solca, F; Zips, D | 1 |
| Amelsberg, A; Burger, H; de Vries, EG; Eskens, FA; Gietema, JA; Huisman, H; Mom, CH; Planting, AS; Stopfer, P; van Doorn, L; Verweij, J | 1 |
| Ambrogio, L; Baum, A; Chirieac, LR; Greulich, H; Himmelsbach, F; Kubo, S; Li, D; Meyerson, M; Padera, RF; Rettig, WJ; Shapiro, GI; Shimamura, T; Solca, F; Takahashi, M; Wong, KK | 1 |
| Balak, M; Bean, J; Ladanyi, M; Marks, JL; Miller, VA; Pao, W; Riely, GJ | 1 |
| Berezov, A; Minkovsky, N | 1 |
| Borgman, CL; Brandstetter, KA; Bronson, RT; Chen, L; Chesa, PG; Chirieac, LR; Greulich, H; Guertler, U; Ji, H; Kubo, S; Li, D; Meyerson, M; Padera, RF; Perera, SA; Raso, MG; Shapiro, GI; Shimamura, T; Solca, F; Takahashi, M; Wistuba, II; Wong, KK; Zaghlul, S | 1 |
| Costa, DB; Kobayashi, S; Nguyen, KS | 1 |
| Amir, E; Ocaña, A | 1 |
| de Stanchina, E; Goel, A; Gong, Y; Koutcher, JA; Mellinghoff, IK; Ouerfelli, O; Pao, W; Politi, KA; Regales, L; Shen, R; Spassova, M; Vivanco, I; Zakowski, MF | 1 |
| Chen, TH; Fischer, F; Getlik, M; Greulich, H; Heuckmann, JM; Heynck, S; Klüter, S; Koker, M; Pawar, VG; Peifer, M; Rabiller, M; Rauh, D; Reuter, C; Rode, HB; Ruddigkeit, L; Simard, JR; Sos, ML; Thomas, RK; Weiss, J; Yuza, Y | 1 |
| Belani, CP | 1 |
| Fukuoka, M; Kuwata, K; Nakagawa, K; Nishio, K; Okamoto, I; Takezawa, K; Tanizaki, J; Yamaguchi, H | 1 |
| Rudman, SM; Spicer, JF | 1 |
| Adam, J; Ang, J; Bell, S; Calvert, H; de Bono, JS; Futreal, A; Plummer, R; Shahidi, M; Shaw, H; Spicer, J; Stephens, P; Stopfer, P; Temple, G; Uttenreuther-Fischer, M; Vidal, L; Yap, TA | 1 |
| Costanzo, R; Daniele, G; Di Maio, M; Giordano, P; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Riccardi, MG; Rocco, G | 1 |
| Hwang, J; Subramaniam, DS | 1 |
| Früh, M | 1 |
| Crinò, L; Metro, G | 1 |
| Essapen, S; Khelwatty, SA; Modjtahedi, H; Seddon, AM | 1 |
| Hirsh, V | 2 |
| Amellal, N; Andre, T; Bouche, O; De Gramont, A; Ducreux, M; Lledo, G; Maindrault-Goebel, F; Merger, M; Stopfer, P | 1 |
| André, T; Battistella, A; Boudou, P; Cervera, P; Chibaudel, B; de Gramont, A; Dumont, S; El Ouadrani, K; Escargueil, AE; Fléjou, JF; Kamsu-Kom, N; Larsen, AK; Mégalophonos, VF; Ouaret, D; Petitprez, A; Poindessous, V; Tournigand, C | 1 |
| Dalgleish, AG; Guertler, U; Ioannou, N; Mackintosh, D; Modjtahedi, H; Seddon, AM; Solca, F | 1 |
| Murakami, H; Naito, T; Nakamura, Y; Nishio, K; Nokihara, H; Sarashina, A; Seki, Y; Shahidi, M; Takahashi, T; Tamura, T; Yamamoto, N | 1 |
| Arcila, ME; Capelletti, M; Eck, MJ; Ginsberg, MS; He, M; Jänne, PA; Kris, MG; Ladanyi, M; Miller, VA; Nafa, K; Oxnard, GR; Yun, CH; Zhao, B | 1 |
| Ebner, T; Gansser, D; Marzin, K; Narjes, H; Shahidi, M; Stopfer, P; Uttereuther-Fischer, M | 1 |
| Abolhoda, A; Ahn, JS; Ahn, MJ; Cui, Z; Kim, Y; Ko, J; Ou, SH; Park, K | 1 |
| Ou, SH | 1 |
| Awada, A; Bozovic-Spasojevic, I; Chow, L | 1 |
| Chen, L; Guan, X; Li, D; Nie, W; Shao, J; Tang, L; Wang, Y; Zhang, H | 1 |
| De Grève, J; De Mey, J; Decoster, L; Everaert, H; Galdermans, D; Geers, C; In't Veld, P; Schallier, D; Teugels, E; Umelo, I | 1 |
| Carey, LA; Cleator, S; Frakes, L; Garcia, AA; Hickish, T; Houston, S; Jones, H; Kelly, S; Lin, NU; Mendelson, D; Munster, P; Uttenreuther-Fischer, M; Vinisko, R; Wheatley, D; Wind, S; Winer, EP | 1 |
| Chen, G; De Grève, J; Kronenberger, P; Teugels, E; Umelo, IA | 2 |
| Bunn, PA; Hirsch, FR | 1 |
| Chang, GC; Cong, XJ; Dudek, AZ; Ho, CL; Hsia, TC; Lorence, RM; Miller, VA; Ou, SH; Sequist, LV; Shahidi, M; Shih, JY; Su, WC; Tsai, CM; Yang, JC; Yang, PC; Yu, CJ | 1 |
| Cadranel, J; Chao, TY; Chen, YM; Cong, XJ; Crino, L; Heo, DS; Hirsh, V; Kim, SW; Lorence, RM; Miller, VA; Park, K; Shahidi, M; Su, WC; Sun, Y; Tan, EH; Wang, M; Yang, JC; Zhou, C | 1 |
| Baird, RD; Barton, DP; Kaye, SB; Khan, AZ; Moreno, V; Vitfell-Pedersen, J; Yap, TA | 1 |
| Dietlein, M; Kahraman, D; Kobe, C; Neumaier, B; Nogova, L; Scheffler, M; Thomas, R; Wolf, J; Zander, T | 1 |
| Awada, A; Beckmann, MW; Besse-Hammer, T; Canon, JL; De Grève, J; Dirix, L; Fasching, PA; Fleischer, F; Gottschalk, N; Harbeck, N; Harter, P; Jonat, W; Neven, P; Piccart, M; Possinger, K; Schmidt, M; Schuler, M; Schütte, J; Uttenreuther-Fischer, M; Wind, S | 1 |
| Adolf, GR; Bader, G; Dahl, G; Haaksma, E; Himmelsbach, F; Klein, C; Kraemer, O; Sanderson, M; Solca, F; Zoephel, A | 1 |
| Cho, BC; Christensen, JG; Ha, SJ; Hong, YK; Kim, JH; Kim, SM; Kwon, OJ; Lee, JH; Solca, F; Soo, RA | 1 |
| Arcila, ME; de Stanchina, E; Janjigian, YY; Kris, MG; Ladanyi, M; Melnick, MA; Miller, VA; Nebhan, CA; Ohashi, K; Pao, W; Pirazzoli, V; Politi, K; Riely, GJ; Song, X; Spitzler, PJ; Takezawa, K | 1 |
| Al-Shahrour, F; Alexander, D; Baran, M; Carretero, J; Difilippantonio, S; El Meskini, R; Guerin, T; Gumprecht, M; Iacovelli, AJ; Kozlov, S; Kulaga, A; Martin, PL; McCann, T; Mena, S; Schlomer, J; Van Dyke, T; Weaver, Z; Wong, KK | 1 |
| Dziadziuszko, R; Jassem, J | 1 |
| Bozovic-Spasojevic, I; de Azambuja, E; Zardavas, D | 1 |
| Cheng, AL; Cheng, JC; Ho, PY; Pu, YS; Tsai, YC; Tuan, TF; Tzen, KY; Yeh, CH | 1 |
| Teh, BW; Worth, LJ | 1 |
| Awada, AH; Besse-Hammer, T; Dumez, H; Fleischer, F; Hendlisz, A; Piccart, M; Schöffski, P; Stopfer, P; Uttenreuther-Fischer, M; Wolter, P | 1 |
| Burger, H; Cohen, RB; Eskens, FA; Hwang, J; Lewis, NL; Malik, S; Marshall, J; Ould-Kaci, M; Stopfer, P; Uttenreuther-Fischer, M | 1 |
| Printz, C | 1 |
| Agus, DB; Gordon, MS; Gross, M; Mendelson, DS; Ould-Kaci, M; Stopfer, P; Uttenreuther-Fischer, M; Zhao, Y | 1 |
| Ehrnrooth, E; Lahogue, A; Machiels, JP; Pelling, K; Rottey, S; Vermorken, JB; Wind, S | 1 |
| Cadranel, J; Cong, XJ; Fairclough, D; Finnern, HW; Hirsh, V; Lorence, RM; Miller, VA; Palmer, M; Yang, JC | 1 |
| Majem, M; Pallarès, C | 1 |
| Dalgleish, A; Ioannou, N; Mackintosh, D; Modjtahedi, H; Seddon, AM | 1 |
| Fujii, A; Furuyama, K; Giaccone, G; Harada, T; Ijichi, K; Iwama, E; Li, H; Nakanishi, Y; Okamura, K; Ota, K; Shiraishi, Y; Takayama, K; Wang, S | 1 |
| Chekaluk, Y; Du, J; Gray, NS; Guo, Y; Kwiatkowski, DJ; Wu, CL; Zhang, J | 1 |
| Gordon, MS; Marshall, J; Ould-Kaci, M; Shapiro, GI; Stopfer, P; Uttenreuther-Fischer, M | 1 |
| Couraud, S | 1 |
| Honda, Y; Ichihara, E; Kiura, K; Kubo, T; Kudo, K; Minami, D; Murakami, T; Ninomiya, T; Ochi, N; Takigawa, N; Tanimoto, M | 1 |
| Chu, CY; Hauschild, A; Lacouture, ME; O'Brien, D; Schadendorf, D; Stammberger, U; Uttenreuther-Fischer, M | 1 |
| Barinoff, J; Cohen, EE; Köhler, J; O'Brien, D; Reguart, N; Stammberger, U; Uttenreuther-Fischer, M; Wolf, J; Yang, JC | 1 |
| Chen, G; De Grève, J; Kronenberger, P; Noor, A; Teugels, E; Umelo, IA | 1 |
| Carbonetti, G; Carlin, SD; Chiosis, G; de Stanchina, E; Divilov, V; Gomes-DaGama, EM; Holland, JP; Janjigian, YY; Lewis, JS; Viola-Villegas, N | 1 |
| Au, JS; Brown, C; Chu, da T; Gebski, V; Gralla, RJ; Hirsh, V; Ho, JC; Inoue, A; Lee, CK; Lee, SM; Osorio Sanchez, JA; Tan, EH; Thongprasert, S; Tsai, CM; Vu, VV; Yang, JC; Zaatar, A | 1 |
| Barlesi, F; Beau-Faller, M; Besse, B; Blons, H; Chouaid, C; Cortot, AB; Dansin, E; Diebold, J; Felip, E; Gautschi, O; Lepage, B; Mansuet-Lupo, A; Mazières, J; Milia, JD; Moro-Sibilot, D; Peters, S; Rouquette, I; Urban, T; Wislez, M | 1 |
| Chen, X; Liu, Y; Pei, D; Schuler, M; Shu, Y; Yin, Y; Zhu, L; Zhu, Q | 1 |
| Gajiwala, KS | 1 |
| Bhave, S; Bruno, PA; Datta, J; Lang, JC; Mapp, AK; Pan, Q; Piao, L; Su, T; Taylor, CE; Teknos, TN; Xie, X; Zhang, M | 1 |
| Becerra, CR; Chand, VK; Cheng, WF; Cohen, SM; Iafrate, AJ; Kwak, EL; Le Maulf, F; Lenz, HJ; Lobmeyer, MT; Robohn, M; Shapiro, GI; Su, WC | 1 |
| Erhardt, J; Goeldner, RG; Schmid, M; Stopfer, P; Wind, S | 1 |
| Aherne, ST; Clynes, M; Crown, J; Doolan, P; Madden, SF; O'Connor, R; O'Neill, F | 1 |
| Bennouna, J; Boyer, M; Geater, SL; Gorbunova, V; Hirsh, V; Kato, T; Lee, KH; Massey, D; Mok, T; O'Byrne, K; Orlov, S; Schuler, M; Sequist, LV; Shah, R; Shahidi, M; Su, WC; Tsai, CM; Yamamoto, N; Yang, JC; Zazulina, V | 1 |
| Atagi, S; Ebisawa, R; Goto, K; Hida, T; Horai, T; Ichinose, Y; Inoue, A; Katakami, N; Kiura, K; Koboyashi, K; Nishio, K; Seki, Y; Shahidi, M; Takeda, K; Yamamoto, N | 1 |
| Hirsh, V; Lungershausen, J; Massey, D; Mok, TS; O'Byrne, KJ; Palmer, M; Schuler, M; Sequist, LV; Shahidi, M; Yamamoto, N; Yang, JC; Zazulina, V | 1 |
| Cho, BC; Hong, YK; Kim, HJ; Kim, JH; Kim, SM; Solca, F; Yun, MR | 1 |
| Thompson, CA | 1 |
| Pao, W; Yu, HA | 1 |
| Langer, CJ | 1 |
| Dungo, RT; Keating, GM | 1 |
| Popat, S; Yap, TA | 1 |
| Sanderson, K | 1 |
| Blendy, JA; Everett, L; Jepson, C; Kaestner, KH; Lee, B; Lerman, C; Ray, R; Turner, JR; Xiang, J | 1 |
| Köhler, J; Schuler, M | 2 |
| Gilbert, JA | 1 |
| Kümler, I; Nielsen, DL; Tuxen, MK | 1 |
| Alam, S; Bent, L; de Bono, J; Kristeleit, H; Middleton, G; Molife, LR; Propper, D; Rudman, SM; Spicer, J; Stopfer, P; Tan, DS; Uttenreuther-Fischer, M; Wallenstein, G | 1 |
| Bowles, DW; Jimeno, A; Weickhardt, A | 1 |
| Gyõrffy, B; Mihály, Z | 1 |
| Costa, DB; de Figueiredo-Pontes, LL; Gonzalez, DA; Kobayashi, S; Lucena-Araujo, AR; Nakayama, S; Yamaguchi, N; Yasuda, H | 1 |
| Ferrarotto, R; Gold, KA | 1 |
| Gauler, TC; Harbeck, N; Solca, F | 1 |
| Nakagawa, T; Yano, S | 1 |
| Cao, F; Fan, FT; Kang, XH; Wang, LF; Xu, ZY | 1 |
| Ebi, H; Ishikawa, D; Matsumoto, K; Nakagawa, T; Nanjo, S; Nishihara, H; Sano, T; Takeuchi, S; Yamada, T; Yano, S; Yasumoto, K; Zhao, L | 1 |
| Bertulis, J; Brand, T; Gansser, D; Giessmann, T; Hocke, J; Jungnik, A; Marzin, K; Stopfer, P; Wind, S | 1 |
| Keating, GM | 2 |
| Feng, J; Geater, SL; Hou, M; Hu, CP; Huang, Y; Kim, M; Lee, KY; Li, W; Lu, S; Massey, D; Shi, JH; Shi, Y; Wu, YL; Xu, CR; Zhou, C | 1 |
| Garassino, MC; Torri, V | 1 |
| Barry, ST; Eberlein, C; Farren, M; Rooney, C; Ross, SJ; Weir, HM | 1 |
| Bloomfield, D; de Bono, JS; Fong, PC; Heath, C; Hickish, T; Jenkins, P; Jones, RJ; Karavasilis, V; Lumsden, G; Molife, LR; O'Sullivan, JM; Olmos, D; Omlin, A; Oommen, N; Pedley, I; Pelling, K; Temple, G; Thompson, E; Wheatley, D | 1 |
| Cinquini, M; De Braud, F; Garassino, MC; Gelsomino, F; Haspinger, ER; Torri, V | 1 |
| de Marinis, F; Passaro, A | 1 |
| Sequist, LV; Yang, JC | 2 |
| Fleury, A; Freiwald, M; Schmid, U; Staab, A; Stopfer, P; Wind, S | 1 |
| Song, T; Wu, SX; Yu, W | 1 |
| Dinglin, X; Fang, W; Hou, X; Hu, Z; Huang, P; Huang, Y; Liang, W; Ma, Y; Qin, T; Tian, Y; Wu, X; Xue, C; Yan, Y; Yang, Y; Zhang, J; Zhang, L; Zhao, H; Zhao, Y; Zhou, T | 1 |
| Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O | 1 |
| Aerts, L; Lauwers, N; Smets, RM | 1 |
| Karachaliou, N; Morales-Espinosa, D; Rosell, R; Viteri, S | 1 |
| Chen, Y; Feng, Z; He, Q; Liang, C; Meng, L; Shu, M; Yang, D; Yu, K; Zhao, H | 1 |
| Cho, BC; Michel, MC; Modjtahedi, H; Solca, F | 1 |
| Alama, A; Barletta, G; Biello, F; Boccardo, F; Burrafato, G; Coco, S; Dal Bello, MG; Genova, C; Grossi, F; Rijavec, E; Truini, A | 1 |
| Kurzrock, R; Parker, BA; Schwab, R; Yan, M | 1 |
| Qi, WX; Shen, Z; Sun, YJ; Yao, Y | 1 |
| Ali, CW; Bates, AT; Button, M; Califano, R; Chan, S; Chaudhuri, A; Danson, SJ; Dorey, N; Dua, D; Ellis, S; Khan, F; Lee, L; Mulvenna, P; Nicolson, M; Ottensmeier, C; Popat, S; Shaw, HM; Szabo, M; Upadhyay, S | 1 |
| de Antonellis, P | 1 |
| Guo, L; Li, M; Liu, Z; Meng, Q; Shi, L; Tang, J; Tao, H; Tong, L; Wu, H; Wu, W; Xu, L; Zhu, Y | 1 |
| Munster, PN; Zhang, X | 1 |
| de Castro, G; Haaland, B; Lopes, G; Tan, PS | 1 |
| Cai, G; Carbone, DP; de Stanchina, E; Gale, M; Gettinger, S; Horn, L; Jia, P; Miller, V; Nebhan, C; Pao, W; Pirazzoli, V; Politi, K; Shapiro, EM; Song, X; Stephens, PJ; Walther, Z; Wurtz, A; Yin, R; Zhao, Z | 1 |
| Aichler, M; Buck, A; Eickelberg, O; Fernandez, IE; Hauck, SM; Huber, K; Janssen, KP; Keller, U; Li, Z; Sun, N; Walch, A; Zitzelsberger, H | 1 |
| Ali, SM; Chan, CA; Halmos, B; Jia, Y; Miller, VA; Saad, S | 1 |
| Liu, C; Qu, G; Sun, B; Wang, P; Zhang, Z; Zhou, C | 1 |
| Agrawal, R; Kumar, S | 1 |
| Nakanishi, Y | 1 |
| Al-Batran, SE; Allgäuer, M; Atmaca, A; Jäger, E | 1 |
| Costa, DB; Gandhi, L; Gerber, DE | 1 |
| Ahn, JS; Ahn, MJ; Cho, BC; Kim, M; Kim, SW; Lee, DH; Massey, D; Park, K; Shi, Y; Sun, JM | 1 |
| Harbeck, N; Hurvitz, SA; Shatsky, R | 1 |
| Fore, M; Mennecier, B; Prim, N | 1 |
| Buschke, S; Fuchs, H; Gansser, D; Goeldner, RG; Halabi, A; Koenen, R; Petersen-Sylla, M; Schnell, D; Stopfer, P; Uttenreuther-Fischer, M; Wind, S | 1 |
| Ardizzoni, A; Artioli, F; Bersanelli, M; Lucchi, L; Tiseo, M | 1 |
| Blackman, A; Clement, PM; Cohen, EEW; Cupissol, D; Degardin, M; Del Campo, JM; Ehrnrooth, E; Fayette, J; Hitt, R; Seiwert, TY; Zhang, W | 1 |
| Fonseca, T; Griebsch, I; Lungershausen, J; Mok, T; Paz-Ares, L; Popat, S; Stammberger, U; Wu, YL; Yang, JC | 1 |
| Chang, J; Cheng, CC; Guan, SS; Ho, AS; Liu, SH; Luo, TY; Wang, CC; Wu, CT | 1 |
| de Marinis, F; Del Signore, E; Di Maio, M; Gori, B; Passaro, A | 1 |
| Fu, LW; He, JH; Huang, ZC; To, KK; Wang, F; Wang, XK; Xu, JH; Ye, S; Zhang, H | 1 |
| Cohen, EE; Haddad, RI; Licitra, LF; Machiels, JP; Tahara, M | 1 |
| Bennouna, J; Bensadoun, RJ; Dielenseger, P; Malka, D; Moro-Sibilot, D; Mortier, L; Rey, JB; Scotté, F; Sicard, J; Wislez, M | 1 |
| Ho, CC; Kuo, YW; Lin, CH; Lin, MT | 1 |
| Chand, VK; Chu, QS; Hirte, HW; Hotte, SJ; Sangha, R; Schnell, D; Sergenson, G | 1 |
| Niessen, HG; Poot, AJ; Schuit, RC; Slobbe, P; Smit, EF; Solca, F; Stehle, G; Stigter-van Walsum, M; van Dongen, GA; Windhorst, AD | 1 |
| Camidge, DR; Chand, VK; Fu, Y; Gettinger, S; Groen, HJ; Horn, L; Janjigian, YY; Miller, VA; Pao, W; Riely, GJ; Smit, EF; Wang, B | 1 |
| Azuma, K; Hoshino, T; Izumi, H; Kage, M; Kawahara, A; Kuwano, M; Nakashima, K; Ono, M; Sonoda, K; Tashiro, K; Watari, K | 1 |
| Cong, J; Cseh, A; Eisenstat, DD; Fu, Y; Kavan, P; Mason, WP; Mathieu, D; Nabors, LB; Perry, JR; Phuphanich, S; Reardon, DA; Shapiro, W; Wind, S | 1 |
| Carretero, J; Costa, DB; Hayashi, Y; Kobayashi, SS; Li, D; Nakayama, S; Sng, N; Soejima, K; Soo, RA; Tan, AJ; Welner, R; Wong, KK; Yamaguchi, N; Yamamoto, M; Yasuda, H | 1 |
| Fang, W; Hong, S; Hu, Z; Kang, S; Liang, W; Qin, T; Sheng, J; Wu, X; Yan, Y; Zhang, L; Zhang, Y | 1 |
| Fischer, JR; Grohé, C; Gütz, S; Kimmich, M; Laack, E; Märten, A; Schneider, CP; Schuler, M; Thomas, M | 1 |
| Arriola, E; Artal, A; Cobo, M; Esteban, E; García-Campelo, R; García-Muret, MP; Reguart, N; Rodríguez, MC | 1 |
| Banna, G; Cappuzzo, F; Catino, A; Chiari, R; Cortinovis, D; Crinò, L; D'Incecco, A; de Marinis, F; Facchinetti, F; Galetta, D; GiajLevra, M; Haspinger, ER; Landi, L; Milella, M; Minuti, G; Novello, S; Ricciardi, S; Rossi, E; Salvini, J; Santo, A; Tibaldi, C; Tiseo, M | 1 |
| Dickgreber, NJ; Hoffknecht, P; Maria Huber, R; Märten, A; Pelzer, T; Schütz, M; Serke, M; Stöhlmacher-Williams, J; Tufman, A; Wehler, T; Wiewrodt, R | 1 |
| Aichler, M; Borgmann, DM; Feuchtinger, A; Hauck, SM; Huber, K; Keller, U; Li, Z; Schwaiger, M; Walch, A; Zitzelsberger, H | 1 |
| Azodi, M; Bellone, S; Bonazzoli, E; Bortolomai, I; Cocco, E; English, DP; Lopez, S; Nicoletti, R; Ratner, E; Roque, DM; Rutherford, TJ; Santin, AD; Schwab, CL; Schwartz, PE; Silasi, DA | 1 |
| Costa, DB; Jorge, SE; Kobayashi, SS | 1 |
| Alama, A; Ballestrero, A; Barletta, G; Boccardo, F; Carminati, E; Coco, S; Dal Bello, MG; Garuti, A; Genova, C; Grossi, F; Rijavec, E; Sini, C; Truini, A; Venè, R | 1 |
| Ali, SA; Burotto, M; O'Sullivan Coyne, G | 1 |
| Engle, JA; Kolesar, JM | 1 |
| Ellis, S; Fayers, PM; Griebsch, I; Palmer, M | 1 |
| Hatcher, H; Laing, R; Pelling, K; Plummer, R; Ring, A; Schnell, D; Temple, G; Uttenreuther-Fischer, M; Wheatley, D | 1 |
| Jeong, EH; Kim, CH; Kim, HR; Kim, SY; Lee, TG | 1 |
| Jain, P; Khanal, R; Sharma, A; Sharma, N; Yan, F | 1 |
| Jenks, S | 1 |
| Bourhis, JP; Burtness, B; Cohen, EE; Harrington, KJ; Vermorken, JB | 1 |
| Fu, LW; Huang, LY; Huang, ZC; To, KK; Wang, F; Wang, XK; Xu, JH; Yang, K; Ye, S | 1 |
| Braun, M; Cassidy, J; Chau, I; Falk, S; Finnigan, H; Ford, H; Harrison, M; Hickish, T; Iveson, T; Jones, H; Lee, C; Macpherson, IR; Potter, V; Propper, D | 1 |
| Baumann, M; Ebert, N; Eicheler, W; Gurtner, K; Krause, M; Pfitzmann, D; Zips, D | 1 |
| Fukuhara, T; Ichinose, M; Kosai, H; Maemondo, M; Mochizuki, M; Nukiwa, T; Ogama, N; Osanai, N; Satoh, K; Tamai, K; Tanaka, N; Watanuki, Z; Yamaguchi, K | 1 |
| Chen, X; Cross, DA; de Stanchina, E; Eisenberg, R; Hutchinson, KE; Jia, P; Jin, H; Ladanyi, M; Lovly, CM; Lu, P; Meador, CB; Nebhan, CA; Pao, W; Pirazzoli, V; Politi, K; Vuong, H; Wang, L; Zhao, Z | 1 |
| Chiba, M; Shibata, Y | 1 |
| Boeck, S; Bruns, CJ; Camaj, P; Gamba, S; Giessen, C; Haertl, C; Heinemann, V; Laubender, RP; Modest, DP; Stintzing, S; Wang, Y; Zhao, Y | 1 |
| Bidoli, P; Cappuzzo, F; Clementi, L; Cseh, A; Favaretto, A; Finocchiaro, G; Grossi, F; Marchetti, A; Massey, D; Santoro, A; Valente, ML | 1 |
| Balikó, Z; Sárosi, V | 1 |
| Aleixo, SB; Arantes, H; Caleffi, M; Figueira, AC; Gutierrez, C; Nunes de Matos Neto, J; Osborne, CK; Reiriz, AB; Rimawi, MF; Rozas, AA; Solca, F; Souza, SC; Uttenreuther-Fischer, MM | 1 |
| Chang, FY; Chao, CH; Chao, TT; Chen, KF; Chen, YL; Huang, YC; Lai, CC; Shiau, CW; Tsai, YT; Wang, CY; Yu, CJ | 1 |
| Cai, M; Jiang, B; Mao, F; Pan, Y; Shen-Tu, Y; Teng, F; Yang, X | 1 |
| Cooke, LS; Kurtzman, D; Mahadevan, D; Morales, C; Ong, E; Qi, W; Stejskal, AE; Swart, R; Theiss, N; Zhu, M | 1 |
| Baum, A; Cohen, EE; Grushko, TA; Hardeman, A; Liu, J; Olopade, OI; Solca, F; Soneru, C; Young, NR | 1 |
| Di Maio, M; Rossi, A | 1 |
| Bennouna, J; Boyer, M; Feng, J; Geater, SL; Gorbunova, V; Hirsh, V; Hu, CP; Huang, Y; Kato, T; Lee, KH; Lee, KY; Lu, S; Massey, D; Mok, T; O'Byrne, K; Orlov, S; Popat, S; Schuler, M; Sebastian, M; Sequist, LV; Shahidi, M; Su, WC; Tsai, CM; Wu, YL; Yamamoto, N; Yang, JC; Zazulina, V; Zhou, C | 1 |
| Cheng, AL; Cheng, JC; Ho, PY; Liu, WL; Pu, YS; Tsai, YC; Tuan, TF; Tzen, KY | 1 |
| Reguart, N; Remon, J | 1 |
| Alama, A; Barisione, G; Bello, MG; Ferrini, S; Gangemi, R; Grossi, F; Orengo, AM; Truini, M | 1 |
| Canon, JL; Chand, VK; De Grève, J; Decoster, L; Galdermans, D; Graas, MP; Massey, D; Moran, T; Schallier, D; Teugels, E; Vansteenkiste, J; Vuylsteke, P | 1 |
| Batra, SK; Ganti, AK; Haridas, D; Lakshmanan, I; Ponnusamy, MP; Rachagani, S; Seshacharyulu, P; Yan, Y | 1 |
| Ambrosio, F; Barbato, C; Cartenì, G; Mocerino, C; Otero, M; Riccardi, F; Scagliarini, S; Vitale, MG | 1 |
| Nakagawa, K; Okamoto, I; Takeda, M | 1 |
| Chen, X; Huang, H; Ma, S; Wang, B; Wu, K; Zhang, S; Zheng, X | 1 |
| Azuma, H; Sakai, K; Suzuki, S; Takahashi, N | 1 |
| Bernardo, LA; Borger, DR; Costa, C; Costa, DB; Engelman, JA; Fulton, LE; Garcia, AR; Getz, G; Howe, E; Iafrate, AJ; Jänne, PA; Katayama, R; Lockerman, EL; Mermel, CH; Mino-Kenudson, M; Miyoshi, N; Mohamoud, F; Moran, T; Mulvey, HE; Niederst, MJ; Poirier, JT; Ramaswamy, S; Ross, KN; Rudin, CM; Sequist, LV; Shioda, T; VanderLaan, PA | 1 |
| Bierbach, U; Day, CS; Gueble, MJ; Kucera, GL; Pickard, AJ; Qiao, X; Yang, M | 1 |
| Burotto, M; Fojo, T; Manasanch, EE; Wilkerson, J | 1 |
| Abdel-Rahman, O; Elhalawani, H | 1 |
| Blohmer, JU; Burchardi, N; Costa, S; Denkert, C; Eidtmann, H; Engels, K; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kümmel, S; Loibl, S; Paepke, S; Schneeweiss, A; Untch, M; von Minckwitz, G | 1 |
| Castellanos, EH; Horn, L; Rivera, G; Wakelee, H | 1 |
| Chung, C | 1 |
| Banno, E; Hayashi, H; Kobayashi, Y; Mitsudomi, T; Nishio, K; Togashi, Y | 1 |
| Arrieta, O; Bacon-Fonseca, L; de la Garza-Salazar, J; Flores-Estrada, D; López-Macías, D; Macedo-Pérez, EO; Martínez-Hernández, JN; Ramírez-Tirado, LA; Vega-González, MT | 1 |
| Caponigro, F; Clement, PM; Cohen, EE; Cong, XJ; Cupissol, D; de Castro, G; de Souza Viana, L; Del Campo, JM; Ehrnrooth, E; Fayette, J; Gauler, T; Grau, JJ; Guigay, J; Haddad, RI; Keilholz, U; Licitra, LF; Machiels, JP; Tahara, M; Vermorken, JB | 2 |
| Chang, H; Chen, G; Chen, Y; Ding, J; Huang, R; Ji, D; Song, B; Yuan, L | 1 |
| Feng, J; Geater, SL; Hou, M; Hu, CP; Huang, Y; Lee, KY; Li, W; Lu, S; Lungershausen, J; Palmer, M; Shi, JH; Shi, Y; Wu, YL; Xu, CR; Zhou, C | 1 |
| Capelletti, M; Choi, HG; Eck, MJ; Ercan, D; Gray, NS; Jänne, PA; Xie, T; Yun, CH | 1 |
| Gordon, MS; LoRusso, PM; Ould-Kaci, M; Springett, GM; Su, YB; Wind, S; Zhao, Y | 1 |
| Daito, H; Ishikawa, R; Kawashima, A; Kobayashi, K; Maeno, Y; Masumoto, A; Murayama, Y; Okano, T; Shiono, A; Utsugi, H; Yamaguchi, O | 1 |
| Bourhis, J; Economopoulou, P; Psyrri, A | 1 |
| Kagohashi, K; Satoh, H; Tamura, T | 1 |
| Geater, SL; Massey, D; Mok, TS; Ou, SH; Schuler, M; Sequist, LV; Tsai, CM; Wu, YL; Yamamoto, N; Yang, JC; Yu, CJ; Zazulina, V; Zhou, C | 1 |
| James, M; Jeong, JH; Lee, Y; Wang, Y; You, M | 1 |
| Cristofanilli, M; Dawood, S | 1 |
| Hida, T; Kato, T; Kiura, K; Massey, D; Okamoto, I; Seki, Y; Seto, T; Yamamoto, N; Yokoyama, A; Yoshioka, H | 1 |
| Girard, N | 2 |
| Allo, G; Ishizawa, K; John, T; Jurisica, I; Kim, L; Leighl, NB; Li, M; Liu, G; Liu, N; Martin, P; Mascaux, C; Neel, BG; Ng, C; Pham, NA; Pintilie, M; Sakashita, S; Shepherd, FA; Stewart, EL; Sykes, J; Tsao, MS; Waddell, TK; Wang, D; Yanagawa, N; Zhu, CQ | 1 |
| Gow, CH; Liao, WY; Liu, YN; Shih, JY | 1 |
| Ardizzoni, A; Chand, VK; Cobo, M; Felip, E; Gadgeel, SM; Georgoulias, V; Göker, E; Goss, GD; Guclu, SZ; Isla, D; Lee, KH; Li, W; Lu, S; Min, YJ; Morabito, A; Soria, JC; Syrigos, K; Wang, B | 1 |
| Arrieta, O; Baracos, VE; De la Torre-Vallejo, M; López-Macías, D; Macedo-Pérez, EO; Orta, D; Ramírez-Tirado, LA; Sánchez-Lara, K; Turcott, J | 1 |
| Sala González, MÁ | 1 |
| Asano, H; Hashida, S; Maki, Y; Miyoshi, S; Miyoshi, Y; Ohtsuka, T; Shien, K; Soh, J; Suzawa, K; Toyooka, S; Tsukuda, K; Watanabe, M; Yamamoto, H | 1 |
| Hida, T; Jangchul, P; Kobayashi, Y; Kondo, C; Mitsudomi, T; Mizuuchi, H; Nishio, K; Sato, K; Shimoji, M; Suda, K; Takemoto, T; Togashi, Y; Tomizawa, K; Yatabe, Y | 1 |
| Azzoli, CG | 1 |
| Datta, J; Lang, JC; Mapp, AK; Pan, Q; Piao, L; Teknos, TN; Xie, X; Zhang, M | 1 |
| Cruz, FM; Del Giglio, A; Normando, SR | 1 |
| Di Luca, A; Henry, M; Meleady, P; O'Connor, R | 1 |
| Bertotti, A; Bose, R; Cottino, F; Galimi, F; Jacobs, SA; Jain, N; Kavuri, SM; Leto, SM; Migliardi, G; Monsey, J; Searleman, AC; Shen, W; Trusolino, L | 1 |
| Ando, Y; Ishiguro, H; Masuda, N; Mitsuma, A; Mukai, H; Sarashina, A; Shibata, T; Toi, M; Uttenreuther-Fischer, M; Watabe, A; Yamamura, J | 1 |
| Ali, SM; Bailey, M; Chandramohan, R; Gallant, JN; Kris, MG; Ladanyi, M; Lipson, D; Lovly, CM; Meiler, J; Miller, VA; Pietenpol, JA; Red Brewer, M; Shaver, TM; Sheehan, JH; York, SJ | 1 |
| Ang, JE; de Bono, J; Harris, D; Kristeleit, R; Kyle, F; Pelling, K; Pemberton, K; Rudman, S; Schnell, D; Solca, F; Spicer, J; Suder, A; Uttenreuther-Fischer, M | 1 |
| Bertotti, A; Catalano, I; Leto, SM; Migliardi, G; Sassi, F; Throsby, M; Torri, V; Trusolino, L; Zanella, ER | 1 |
| Chen, D; Fan, C; Li, Y; Yang, Y; Zhang, L; Zhao, S; Zheng, Q; Zheng, S; Zhou, H | 1 |
| Marquez-Medina, D; Popat, S | 1 |
| Cai, Y; Li, GF; Liang, QY; Liu, ST; Liu, Y; Song, ZH; Sun, YB; Wang, SQ; Wang, YT; Yang, FH; Zhao, BX | 1 |
| Bianco, R; Carillio, G; Costanzo, R; Daniele, G; Giordano, P; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Azuma, Y; Futagami, S; Hamaguchi, M; Hikita, A; Hirashima, T; Iwata, K; Morishita, N; Okamoto, N; Ryota, N; Sando, M; Shiroyama, T; Suzuki, H; Tamiya, M; Tanaka, A; Tani, E | 1 |
| Cosmai, L; Gallieni, M; Porta, C | 1 |
| Ayeni, D; de Stanchina, E; Goldberg, SB; Hyder, F; Meador, CB; Pao, W; Pirazzoli, V; Politi, K; Sanganahalli, BG | 1 |
| De Smet, M; Herremans, C; Liu, D; Machiels, JP; Peeters, M; Pilz, K; Rottey, S; Specenier, P; Strelkowa, N; Surmont, V | 1 |
| Ettinger, DS; Forde, PM | 1 |
| Griesinger, F; Heigener, DF; Lüers, A; Märten, A; Sadjadian, P; Scheffler, M; Schumann, C; Sebastian, M; Stehle, I | 1 |
| Gilligan, D; Pacey, S; Tan, CS | 1 |
| Almeida, GM; Coelho, MA; Coelho, SC; Pereira, MC; Santos-Silva, F | 1 |
| Abdel-Sattar, M; Sugay, A; Tien Ho, P; Ting, J; Wilson, L; Xiang, P | 1 |
| Iwasa, T; Kaneda, H; Kudo, K; Nakagawa, K; Nishida, S; Nishio, K; Okamoto, I; Takahama, T; Takeda, M; Tanaka, K; Yonesaka, K; Yoshida, T | 1 |
| Alshami, J; Cseh, A; Gibson, N; Guiot, MC; Kavan, P; Muanza, T; Owen, S; Reardon, DA; Solca, F | 1 |
| Cappuzzo, F; D'Incecco, A; Minuti, G | 1 |
| Barber, TA; Engelman, JA; Fleisher, M; Fox, DB; Giri, U; Haber, DA; Heymach, JV; Jänne, PA; Johnson, BE; Kapur, R; Koch, WH; Maher, R; Maheswaran, S; Muzikansky, A; Riely, GJ; Sequist, LV; Stott, SL; Sullivan, JP; Sundaresan, TK; Toner, M; Tran, HT; Walsh, JR; Webb, A; Wei, W; Yu, HA | 1 |
| Cui, Y; Gong, Y; Kang, X; Lu, P; Wang, Y; Xu, Z; Zhang, Q | 1 |
| Fang, YF; Hsieh, MH; Li, SH | 1 |
| Amellal, N; Bahleda, R; Deutsch, E; Farace, F; Gazzah, A; Hollebecque, A; Marzin, K; Massard, C; Ould-Kaci, M; Roux, F; Soria, JC; Varga, A | 1 |
| Hayashi, H; Hirose, C; Iihara, H; Itoh, Y; Kita, Y; Kitaichi, K; Minatoguchi, S; Ohno, Y; Sugiyama, T; Todoroki, K; Yamada, M; Yanase, K | 1 |
| Asano, H; Hashida, S; Maki, Y; Miyoshi, S; Morita, M; Ohtsuka, T; Sakaguchi, M; Soh, J; Suzawa, K; Tomida, S; Toyooka, S; Tsukuda, K; Watanabe, M; Yamamoto, H | 1 |
| Abdel-Rahman, O; Ahmed, H; ElHalawani, H | 1 |
| Arcila, ME; Chaft, JE; Cooper, W; Kris, MG; Lee, A; Li, BT; O'Toole, S; Pavlakis, N; Yu, B | 1 |
| Protsenko, SA; Rudakova, AV | 1 |
| Iwasa, T; Kaneda, H; Nakagawa, K; Nonagase, Y; Okamoto, K; Shimizu, T; Takeda, M; Tanaka, K; Tsurutani, J; Yoshida, T | 1 |
| Chen, CS; Chen, CY; Chen, JJ; Hong, TM; Hsiao, TH; Huang, KY; Kao, SH; Salunke, SB; Su, KY; Wang, WL; Yang, PC; Yang, SC | 1 |
| Bachelot, T; Barriere, J; Bono, P; Ciruelos, E; Cortés, J; Dieras, V; Espié, M; Hurvitz, S; Joensuu, H; Kellokumpu-Lehtinen, PL; Kim, SB; Le Rhun, E; Nabholtz, JM; Ould-Kaci, M; Piacentini, F; Ro, J; Roux, F; Schneeweiss, A; Sohn, JH; Taguchi, J | 1 |
| Lin, NU | 1 |
| Barlesi, F; Beau-Faller, M; Besse, B; Cappuzzo, F; Cortot, A; Dansin, E; Filleron, T; Fournel, P; Früh, M; Gautschi, O; Mazières, J; Milia, J; Monnet, I; Moro-Sibilot, D; Peters, S; Pless, M; Rosell, R; Westeel, V; Wislez, M | 1 |
| Inoue, A; Nakamura, M; Nishio, D; Sawada, Y | 1 |
| Bennouna, J; Moreno Vera, SR | 1 |
| Barone, C; Basso, M; Cassano, A; Cerchiaro, E; D'Argento, E; Dadduzio, V; Martini, M; Rossi, S; Strippoli, A | 1 |
| Bennouna, J; Chand, VK; Chen, YM; Chouaid, C; De Marinis, F; Feng, JF; Grossi, F; Kim, DW; Kim, JH; Liu, X; Lu, S; Park, K; Planchard, D; Schuler, M; Strausz, J; Vinnyk, Y; Wang, B; Wiewrodt, R; Yang, JC; Zhou, C | 1 |
| Chen, KL; Cho, YT; Chu, CY; Lin, CC; Sheen, YS; Tsai, HE; Yang, CW | 1 |
| Ahn, JS; Ahn, MJ; Bae, YH; Jung, KS; Kim, HS; Koh, J; Ku, BM; Lee, JY; Lee, SH; Lim, SH; Park, K; Song, HN; Sun, JM; Yoo, KH | 1 |
| Favaudon, V; Fernet, M; Giocanti, N; Huguet, F; Larsen, AK | 1 |
| Liu, YH; Zhu, WL | 1 |
| Abdelhameed, AS; Al-Shakliah, NS; Attwa, MW; Darwish, HW; Kadi, AA | 1 |
| Bonerigo, S; Chung, CH; Cmelak, A; Gilbert, J; John, P; Kang, H; Kiess, A; Marur, S; Murphy, BA; Quon, H; Rudek, MA; Tsottles, N; Veasey, A | 1 |
| Brower, V | 1 |
| Grunt, TW; Gschwantler-Kaulich, D; Kölbl, H; Muhr, D; Singer, CF; Wagner, R | 1 |
| Abdelhameed, AS; Alanazi, AM | 1 |
| Wang, LM; Zhan, WJ; Zhu, JF | 1 |
| Dalgleish, A; Ioannou, N; Mackintosh, D; Modjtahedi, H; Seddon, AM; Solca, F | 1 |
| Asai, K; Hirata, K; Isa, S; Kawaguchi, T; Kimura, T; Kubo, A; Kudoh, S; Matsuura, K; Mitsuoka, S; Nakai, T; Oka, T; Sawa, K; Suzumura, T; Tanaka, H; Uji, M; Watanabe, T; Yoshimoto, N; Yoshimura, N | 1 |
| Brands, RC; De Donno, F; Hartmann, S; Kübler, AC; Linz, C; Müller-Richter, UD; Mutzbauer, G; Seher, A | 1 |
| Atobe, O; Fujimori, A; Hachiya, T; Ikuyama, Y; Imai, A; Shiba, H; Sonehara, K | 1 |
| Chen, SC; Goeldner, RG; Harbeck, N; Huang, CS; Hurvitz, S; Im, SA; Im, YH; Jassem, J; Jung, KH; Piccart-Gebhart, M; Ro, J; Shao, Z; Shen, K; Sun, Q; Uttenreuther-Fischer, M; Wojtukiewicz, M; Xu, B; Yeh, DC; Zhang, Q | 1 |
| Hirsh, V; Massey, D; Mok, T; O'Byrne, K; Popat, S; Schuler, M; Sequist, LV; Wu, YL; Yamamoto, N; Yang, JC; Zazulina, V | 1 |
| Beijnen, JH; Rood, JJ; Schellens, JH; Schinkel, AH; Sparidans, RW; van Hoppe, S | 1 |
| Groen, HJ; Hiltermann, TJ; Kok, K; Saber, A; van den Berg, A; van der Wekken, AJ | 1 |
| Chang, YL; Liu, YN; Shih, JY; Tsai, MF; Wen, YF; Wu, SG; Yang, JC; Yang, PC; Yu, CJ | 1 |
| Syed, YY | 1 |
| Li, G; OuYang, Y; Sun, C; Tu, Y; Xu, S; Zheng, P; Zhu, W; Zhu, Y | 1 |
| Choy, TS; Kwong, DL; Lam, KO; Lam, PM; Lee, VH; Leung, DK; Leung, TW | 1 |
| Bogdanowicz, BS; Hartranft, ME; Hoch, MA | 1 |
| Ke, EE; Wu, YL | 1 |
| Booth, L; Chen, J; Dent, P; Leon, D; McGuire, WP; Poklepovic, A; Roberts, JL; Tavallai, M; Webb, T | 1 |
| Ahn, HJ; Nam, HW; Park, YH; Yang, Z | 1 |
| Lee, VH; Ma, L; Wang, DD; Yan, H; Zhu, G; Zou, B | 1 |
| Costa, DB; Freed, JA; Huberman, MS; Jorge, SE; Kobayashi, SS; Moran, JP; Zerillo, JA | 1 |
| Mehra, R; Zibelman, M | 1 |
| Bessho, A; Fujii, M; Gemba, K; Harita, S; Hotta, K; Inoue, K; Kiura, K; Kozuki, T; Kudo, K; Kuyama, S; Nogami, N; Oda, N; Okada, T; Takigawa, N; Tanimoto, M | 1 |
| Carbonnaux, M; Couraud, S; Meert, AP; Peters, M; Scherpereel, A; Souquet, PJ | 1 |
| Arrieta, O; Astudillo-de la Vega, H; Caballe-Perez, E; Cruz-Rico, G; Macedo-Pérez, EO; Martinez-Alvarez, I; Martínez-Hernández, JN; Ramírez-Tirado, LA; Soca-Chafre, G; Soto-Perez-de-Celis, E | 1 |
| Sakiyama, S; Takizawa, H; Tangoku, A; Toba, H | 1 |
| Brueckl, WM; Debus, D; Doesch, J; Ficker, JH; Meyer, C; Papadopoulos, T; Schultz, ES | 1 |
| Antic, T; Campanile, A; Choudhury, NJ; Fitzpatrick, CA; Karrison, T; Nakamura, Y; O'Donnell, PH; Stadler, WM; Wade, JL; Yap, KL | 1 |
| Contreras-Díaz, M; López-Herrero, F; Martínez-Bernal, G; Medina-Tapia, A; Molina-Socola, FE; Rueda-Rueda, T; Sánchez-Vicente, JL | 1 |
| Gray, J; Grossman, S; Jones, M; Lok, D; Zhang, J | 1 |
| Arvis, CD; Boyer, M; Hirsh, V; Kim, DW; Kim, M; Kim, SW; Kölbeck, K; Laskin, J; Laurie, SA; Lee, KH; Lu, S; Massey, D; Mok, T; O'Byrne, K; Park, K; Paz-Ares, L; Shahidi, M; Shi, Y; Tan, EH; Tsai, CM; Yang, JC; Zazulina, V; Zhang, L | 1 |
| Fang, W; Tian, Y; Xue, C; Zhan, J; Zhang, J; Zhang, L; Zhao, Y | 1 |
| Kim, HR; Kim, JH; Kim, S; Kwack, K; Lee, MG; Lim, SM; Moon, YW; Park, HS | 1 |
| Conte, P; Fassan, M; Frega, S; Pasello, G; Polo, V | 1 |
| Cicchetti, A; Drago, F; Drago, V; Gozzo, L; Longo, L; Mansueto, S; Navarria, A; Pignataro, G; Salomone, S | 1 |
| Specenier, P; Vermorken, J | 1 |
| Banno, E; de Velasco, MA; Fujita, Y; Hamada, S; Hayashi, H; Nakahara, H; Nakamura, Y; Nishio, K; Nutahara, K; Okegawa, T; Sakai, K; Terashima, M; Togashi, Y; Tomida, S | 1 |
| Hattori, Y; Honda, Y; Katsura, S; Manabe, T; Miyachi, Y; Otsuka, A; Terashima, T | 1 |
| Bates, V; Boland, A; Dundar, Y; Dwan, K; Green, JA; Greenhalgh, J; Jain, P; Vecchio, F | 1 |
| De Pauw, I; Deschoolmeester, V; Lardon, F; Pauwels, P; Peeters, M; Van den Bossche, J; Vermorken, JB; Wouters, A | 1 |
| Silakari, O; Singh, H; Singh, PK | 1 |
| Amann, A; Gamerith, G; Huber, JM; Kelm, JM; Koeck, S; Lorenz, E; Obexer, P; Zwierzina, H | 1 |
| López-Brea, M | 1 |
| Álvarez-Fernández, C; Esteban-González, E | 1 |
| Diz Taín, P; García-Palomo, A; González, AL | 1 |
| Vidal, ÓJ | 1 |
| Alejandro, MÁ; Artal Cortés, Á; Gimeno Pelegrín, J | 1 |
| Cobo, M; Godoy, A; Gutiérrez, V; López, O; Rodelo, L; Ruiz, M | 1 |
| Taus, Á | 1 |
| Carroll, KS; Palde, PB; Paulsen, CE; Schlessinger, A; Truong, TH; Ung, PM | 1 |
| Ballard, P; Box, M; Cantarini, M; Cross, D; Grist, M; Hickey, M; Jänne, PA; Johnström, P; Jordan, A; Kim, DW; Malmquist, J; Pickup, K; Thress, KS; Varnäs, K; Yang, JC; Yang, Z; Yates, JW | 1 |
| Burghuber, OC; Hochmair, M; Holzer, S | 1 |
| Butler, R; Davies, RS; Lester, JF; Nelmes, DJ | 1 |
| Ebner, T; Freiwald, M; Schnell, D; Stopfer, P; Wind, S | 1 |
| Chen, T; Gao, N; Hu, Y; Huang, X; Jia, T; Jin, G; Jin, Z; Liu, B; Peng, B; Wang, Z; Zhang, N | 1 |
| Harada, D; Harita, S; Hotta, K; Ichihara, E; Ichikawa, H; Inoue, K; Inoue, M; Kishino, D; Kiura, K; Kubo, T; Kuyama, S; Minami, D; Murakami, T; Ninomiya, K; Ninomiya, T; Oda, N; Shibayama, T; Takigawa, N; Tanimoto, M; Yokoyama, T | 1 |
| He, J; Ma, J; Tan, W; Tang, X | 1 |
| Hayashi, H; Kudo, K; Nakagawa, K; Takeda, M; Ueda, H | 1 |
| Campo, M; Engelman, JA; Fidias, P; Gainor, JF; Gerber, D; Heist, RS; Muzikansky, A; Sequist, LV; Shaw, AT; Temel, JS | 1 |
| Baba, T; Futaki, M; Iwasawa, T; Kato, T; Ogura, T; Sakuranaka, H; Sekine, A; Suido, A | 1 |
| Dickgreber, N; Feng, J; Geater, SL; Hirsh, V; Hu, CP; Huang, Y; Lu, S; Märten, A; Massey, D; Mok, T; O'Byrne, K; Okamoto, I; Schuler, M; Sebastian, M; Sequist, LV; Shah, R; Wind, S; Wu, YL; Yamamoto, N; Yang, JC; Zhou, C | 1 |
| Arrieta, O; Barron, F; Cardona, AF; de la Torre-Vallejo, M; Luna-Palencia, RL | 1 |
| Beijnen, JH; Rood, JJM; Rosing, H; Schellens, JHM; Sparidans, RW | 1 |
| Arai, D; Betsuyaku, T; Hamamoto, J; Hayashi, Y; Hirano, T; Ishioka, K; Kawada, I; Miyawaki, M; Naoki, K; Nukaga, S; Ohgino, K; Soejima, K; Tani, T; Yasuda, H | 1 |
| Aida, Y; Fujita, K; Hida, N; Hizawa, N; Morishima, Y; Nakazawa, K; Sekine, I; Shiozawa, T; Tsunoda, Y | 1 |
| Banno, E; Hayashi, H; Kaneda, H; Nakagawa, K; Nishio, K; Sakai, K; Takeda, M; Tanizaki, J; Togashi, Y | 1 |
| Doki, Y; Fukuoka, J; Hori, T; Isobe, M; Kurose, K; Nakayama, E; Nishio, Y; Nozawa, R; Ohue, Y; Oka, M; Tanaka, T | 1 |
| Bonetti, A; Giuliani, J; Remo, A | 1 |
| Fujimoto, J; Goshima, N; Higa, A; Hiyama, G; Hoshi, H; Inageda, K; Ishikawa, K; Kawamura, Y; Semba, K; Takagi, M; Takahashi, N; Togashi, T; Wakamatsu, A; Watanabe, S | 1 |
| Chang, JC; Iqbal, A; Jakubowski, CD; Paik, PK; Plodkowski, AJ; Rekhtman, N; Yu, HA | 1 |
| Ang, JE; de Bono, J; Enting, D; Irshad, S; Kristeleit, R; Pelling, K; Pemberton, K; Schnell, D; Spicer, J; Uttenreuther-Fischer, M | 1 |
| Agatsuma, T; Gomi, D; Hachiya, T; Hanaoka, M; Koizumi, T; Koyama, S; Kuraishi, H; Miyahara, T; Ono, Y; Suzuki, T; Tateishi, K; Wada, Y; Yamamoto, R; Yoshiike, F | 1 |
| Fujii, S; Kashiwabara, K; Semba, H; Tsumura, S | 1 |
| Brückl, W; Huber, RM; Tufman, A | 1 |
| Asao, T; Hayashi, H; Iihara, H; Imai, H; Itoh, Y; Kaira, K; Kita, Y; Minato, K; Mizusaki, N; Naruse, I; Sugiyama, T; Yamada, M | 1 |
| Chen, Z; Guan, S; Lu, J; Mao, X; Pang, JC; Tao, L; Vasudevan, SA; Woodfield, SE; Yang, J; Yu, Y; Zhang, F; Zhang, H; Zhao, Y | 1 |
| Ali, SM; Bocharov, EV; Campregher, PV; Chung, J; Gitlitz, BJ; Haddad, CK; Johnson, M; Klempner, SJ; Miller, VA; Ou, SI; Ross, JS; Schrock, AB; Steinecker, G; Stephens, PJ; Suh, JH; Velcheti, V | 1 |
| Pakkala, S; Ramalingam, SS | 1 |
| Azuma, K; Chiba, M; Kim, YH; Kobayashi, Y; Mitsudomi, T; Nagai, H; Nishio, K; Sato, K; Sesumi, Y; Shimoji, M; Takemoto, T; Togashi, Y; Tomizawa, K | 1 |
| Afrit, M; Ahmed, SB; Arpornwirat, W; Chitapanarux, I; Dechaphunkul, A; Ganju, V; Gibson, N; Goh, G; Guiver, K; Herrero, J; Im, SA; Johnston, SR; Kim, SB; Maneechavakajorn, J; Schmid, R; Spector, N; Swanton, C; Uttenreuther-Fischer, M; Yau, T | 1 |
| Adamo, V; Franchina, T; Ricciardi, GRR; Russo, A | 1 |
| Hayama, M; Hirashima, T; Morishita, N; Nishida, T; Nishihara, T; Okamoto, N; Shiroyama, T; Suzuki, H; Tamiya, M; Tanaka, A | 1 |
| Feng, J; Gibson, N; Hirsh, V; Hou, M; Hu, CP; Huang, Y; Kim, M; Li, W; Lu, S; Massey, D; Mok, T; O'Byrne, K; Schuler, M; Sequist, LV; Wu, YL; Yamamoto, N; Yang, JC | 1 |
| Bray, V; Ding, PN; Gebski, V; Gralla, RJ; Lee, CK; Links, M; Lord, SJ; Yang, JC | 1 |
| Diebold, J; Froesch, P; Früh, M; Gautschi, O; Jochum, W; Klingbiel, D; Mark, M; Reichegger, H; Rothschild, S; Schmid, S | 1 |
| Bandoh, S; Chiba, Y; Ishii, T; Kadowaki, N; Kanaji, N; Kita, N; Sato, A; Tadokoro, A; Ueno, M; Watanabe, N | 1 |
| Hanaoka, J; Hayashi, H; Iihara, H; Itoh, Y; Kawaguchi, Y; Mizusaki, N; Sugiyama, T | 1 |
| Jänne, PA; Saxon, JA; Sholl, LM | 1 |
| Ali, SM; Allen, JM; Erlich, RL; Miller, VA; Ou, SI; Ross, JS; Schrock, AB; Stephens, PJ; Vafai, D | 1 |
| Go, YJ; Han, JY; Joo, J; Lee, GK; Lee, JS; Lee, KH; Lee, SH; Lee, Y; Lim, KY | 1 |
| Abazeed, ME; Khunger, M; Velcheti, V | 1 |
| Assi, T; El Rassy, E; Ghosn, M; Kattan, J; Moussa, T | 1 |
| Liao, BC; Lin, CC; Yang, JC | 1 |
| Breslin, S; Lowry, MC; O'Driscoll, L | 1 |
| Chuang, JC; Das, M; Diehn, M; Huang, J; Liang, Y; Neal, JW; Stehr, H; Wakelee, HA | 1 |
| Akamatsu, H; Azuma, K; Fukuhara, T; Goto, K; Harada, D; Harada, T; Hotta, K; Iwama, E; Kishimoto, J; Kurata, T; Nakanishi, Y; Nishio, K; Nosaki, K; Ohyanagi, F; Okamoto, I; Sakai, K; Shimose, T | 1 |
| Bai, Y; Black, J; Carvajal-Hausdorf, DE; Rimm, DL; Santin, AD; Schalper, KA | 1 |
| Song, Y; Yuan, DM | 1 |
| Bae, YC; Baek, MC; Ihn, HJ; Kim, JA; Park, EK; Shin, HI | 1 |
| Akashi, K; Harada, T; Ijichi, K; Iwama, E; Nakanishi, Y; Obara, T; Ogata, H; Okamoto, I; Yoshimoto, G | 1 |
| Arteaga, CL; Berger, MF; Brewer, MR; Cross, D; Cutler, RE; Hanker, AB; He, J; Hyman, DM; Koch, JP; Lalani, AS; Lanman, R; Lovly, CM; Meiler, J; Miller, V; Nagy, R; Sheehan, JH; Sliwoski, GR; Solit, DB | 1 |
| Ando, K; Arata, S; Ishida, H; Kusumoto, S; Murata, Y; Ohba, M; Ohmori, T; Ohnishi, T; Sasaki, Y; Yamaoka, T | 1 |
| Feng, Q; Fu, X; Hackshaw, A; Mao, C; Tang, J; Yang, Z; Zhang, Y | 1 |
| Giusti, R; Iacono, D; Lauro, S; Marchetti, P; Mazzotta, M | 1 |
| Awasthi, S; Bansal, M; Belkina, N; Biswas, R; Califano, A; Chaerkady, R; Charles Jacob, HK; Cultraro, CM; Gao, S; Guha, U; Kashyap, MK; Kirkali, G; Maity, T; Marimuthu, A; Pandey, A; Pitts, S; Singh, S; Venugopalan, A; Zhang, X | 1 |
| Li, J; Ma, J; Wang, Y; Wang, Z; Wu, X | 1 |
| Higo, H; Hotta, K; Ichihara, E; Kato, Y; Kayatani, H; Kiura, K; Kubo, T; Kudo, K; Kurata, Y; Makimoto, G; Minami, D; Ninomiya, T; Ohashi, K; Sato, A; Takami, Y; Tanimoto, M; Yoshino, T | 1 |
| Aggarwal, C; Borghaei, H | 1 |
| Belli, V; Ciaramella, V; Ciardiello, F; Della Corte, CM; Malapelle, U; Martinelli, E; Morgillo, F; Pepe, F; Troiani, T; Troncone, G; Vigliar, E | 1 |
| Batra, SK; Ganti, AK; Gupta, S; Jahan, R; Jain, M; Jones, DT; Kibe, T; Kishida, M; Kishida, S; Li, S; Lin, C; Lydiatt, WM; Macha, MA; Nakamura, N; Patel, A; Qazi, AK; Rachagani, S; Seshacharyulu, P; Smith, RB; Verma, V; Wang, S | 1 |
| Boyer, M; Dodd, N; Fan, J; Hirsh, V; Kim, DW; Kölbeck, K; Laskin, J; Laurie, SA; Lee, DH; Lee, KH; Lu, S; Märten, A; Mok, T; O'Byrne, K; Park, K; Paz-Ares, L; Shi, Y; Tan, EH; Yang, JC; Zhang, L | 1 |
| Amin, Z; Jayalie, VF; Rajabto, W | 1 |
| Chen, G; Huang, X; Huang, Y; Kang, S; Miao, S; Wu, M; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H | 1 |
| Altavilla, G; Bulotta, A; Gonzalez-Cao, M; Gregorc, V; Karachaliou, N; Lazzari, C; Rosell, R; Santarpia, M; Verlicchi, A | 1 |
| Beadling, C; Corless, CL; Gay, ND; Neff, T; Tolba, K; Wang, Y; Warrick, A | 1 |
| Bivona, TG; Chaib, I; Codony-Servat, C; Codony-Servat, J; de Los Llanos Gil, M; Karachaliou, N; Molina, MA; Ramirez, JL; Rosell, R; Solca, F | 1 |
| Srinivas, NR | 1 |
| Chen, KL; Cheng, YP; Cho, YT; Chu, CY; Liau, JY; Sheen, YS; Yang, CW | 1 |
| Alias, Z; Karsani, SA; Yahya, MFZR | 1 |
| Ardizzoni, A; Bühnemann, C; Cobo, M; Dupuis, N; Ehrnrooth, E; Felip, E; Gadgeel, S; Georgoulias, V; Göker, E; Goss, G; Guclu, SZ; Isla, D; Krämer, N; Lee, KH; Lu, S; Morabito, A; Solca, F; Soria, JC; Syrigos, K | 1 |
| Schinkel, AH; van Hoppe, S | 1 |
| Duan, YJ; Huo, XK; Liu, KX; Liu, ZH; Ma, XD; Meng, Q; Sun, HJ; Wang, CY; Zhang, Y | 1 |
| Hida, T; Horio, Y; Inaba, Y; Kuroda, H; Oya, Y; Sakao, Y; Shimizu, J; Yatabe, Y; Yoshida, T | 1 |
| Bosch-Barrera, J; Costa, EC; Insa, A; Isla, D; Kraemer, S; Lee, C; Majem, M; Moran, T; Palmero, R; Provencio, M; Puig, M; Reguart, N; Rosell, R; Schnell, D | 1 |
| Atallah, JP; Ibrahim, U; Saqib, A | 1 |
| Honkanen, T; Koivunen, JP; Koivunen, P; Wilenius, E | 1 |
| Chen, SF; Zhang, JL; Zhang, ZY | 1 |
| Bennouna, J | 1 |
| Bernatowicz, PL; Pancewicz-Wojtkiewicz, J | 1 |
| Chen, HJ; Chen, WC; Hsia, TC; Li, CH; Liao, WC; Shen, YC; Tseng, GC; Tu, CY | 1 |
| Corrao, G; Facchinetti, F; Ganzinelli, M; Garassino, MC; Lo Russo, G; Minari, R; Proto, C; Tiseo, M | 1 |
| Chiba, R; Kudo, K; Moriguchi, S; Morikawa, N; Nihei, S; Saito, H; Sato, J; Yamauchi, K | 1 |
| Beretta, GD; Caprioli, A; Ceresoli, GL; Codignola, C; Fraccon, AP; Meriggi, F; Ogliosi, C; Prochilo, T; Scartozzi, M; Zaniboni, A | 1 |
| Collins, DM; Crown, J; Davies, A; Edwards, C; Gately, K; Hughes, C; Madden, SF; O'Byrne, KJ; O'Donovan, N | 1 |
| Atagi, S; Hirashima, T; Imai, K; Isa, SI; Iwazaki, A; Nakao, K; Nishihara, T; Okamoto, N; Okishio, K; Omachi, N; Shiroyama, T; Suzuki, H; Takeuchi, N; Tamiya, A; Tamiya, M; Tsuji, T | 1 |
| Bennouna, J; Chouaid, C; de Pouvourville, G; Do, P; LeLay, K; Luciani, L; Moro-Sibilot, D; Perol, M; Vergnenègre, A | 1 |
| Arimura-Omori, M; Hamada, N; Harada, E; Mikumo, H; Nakanishi, Y; Ogata-Suetsugu, S; Suzuki, K; Yanagihara, T | 1 |
| Chang, CC; Chang, J; Chang, YC; Chang, YF; Cheng, CC; Ho, AS; Huang, L; Huang, SC; Lim, KH; Lin, HC; Wu, CW | 1 |
| Hayashi, R; Inomata, M; Kambara, K; Kashii, T; Konishi, H; Miwa, T; Okazawa, S; Shimokawa, K; Tanaka, H; Tobe, K; Tokui, K; Yamada, T | 1 |
| Groen, HJM; Heideman, DAM; Hiltermann, TJN; Kok, K; Kuiper, JL; Saber, A; Schuuring, E; Smit, EF; Terpstra, MM; Thunnissen, E; Timens, W; van den Berg, A; van der Wekken, AJ; Wei, J | 1 |
| Hamaguchi, R; Hasegawa, M; Okamoto, T; Sato, M; Wada, H | 1 |
| Lai, Y; Sun, X; Tao, L; Wang, Q; Xu, C; Zhang, X; Zhao, Y | 1 |
| Baba, T; Ikeda, S; Iwasawa, T; Kato, T; Ogura, T; Okudela, K; Sekine, A; Yamakawa, H; Yamanaka, Y | 1 |
| Ch'ng, C; Chia, S; Gelmon, K; Ho, C; Ho, J; Ionescu, D; Jones, MR; Jones, SJM; Laskin, J; Leelakumari, S; Lim, H; Ma, Y; Marra, MA; Moore, RA; Mungall, AJ; Mungall, KL; Ng, T; Pleasance, E; Reisle, C; Renouf, DJ; Schaeffer, DF; Shen, Y; Yip, S; Zhao, C; Zhao, Y; Zhong, E | 1 |
| Burtness, B; Clement, PM; Cohen, EEW; Cong, XJ; Del Campo, JM; Dupuis, N; Ehrnrooth, E; Fayette, J; Gauler, T; Geoffrois, L; Gibson, N; Grau, JJ; Guigay, J; Haddad, RI; Krämer, N; Licitra, LF; Machiels, JH; Mailliez, A; Merlano, MC; Solca, F; Tahara, M; Vermorken, JB | 1 |
| Arqués, O; Cedrés, S; Fasani, R; Felip, E; Guillaumet-Adkins, A; Heyn, H; Martinez de Castro, A; Martinez-Marti, A; Matito, J; Mereu, E; Miquel, JM; Nadal, E; Navarro, A; Nuciforo, P; Palmer, HG; Pardo, N; Remon, J; Rodriguez-Esteban, G; Villanueva, A; Vivancos, A | 1 |
| Jiang, Q; Jin, Y; Xin, T | 1 |
| Bhuyan, AAM; Bissinger, R; Cao, H; Gawaz, M; Lang, F; Umbach, AT | 1 |
| Ahn, HJ; Bhatt, L; Kim, YH; Lee, WK; Nam, HW; Yang, Z | 1 |
| Camidge, DR; Chand, VK; Fan, J; Freiwald, M; Gettinger, S; Groen, HJM; Horn, L; Janjigian, YY; Miller, VA; Pao, W; Smit, EF; Wang, B | 1 |
| Diao, L; Fan, Y; Gomez, D; Haddad, V; Herbst, R; Heymach, JV; Hong, WK; Howells, K; Hung, MC; Kim, ES; Lee, JJ; Li, L; Lim, SO; Liu, D; Nilsson, MB; Pena, GA; Poteete, A; Sequist, LV; Sood, AK; Sun, H; Tong, P; Tran, H; Wang, J; Wistuba, I; Yang, JC | 1 |
| Boumber, Y; Chaudhary, S; Kesari, K; Khan, H; Khan, M; Smith, S; Wahab, A | 1 |
| Kodama, K; Maniwa, T; Takeda, M; Yamamoto, Y | 1 |
| Cheema, PK; Doherty, M; Tsao, MS | 1 |
| Fang, YF; Hsu, PC; Kao, KC; Li, SH; Liu, CY; Tseng, LC; Wang, CC; Yang, CT | 1 |
| Feng, J; Geater, SL; Hirsh, V; Hu, CP; Huang, Y; Lu, S; Lungershausen, J; Märten, A; Massey, D; Mok, T; O'Byrne, K; Schuler, M; Sequist, LV; Wu, YL; Yamamoto, N; Yang, JC; Zhou, C | 1 |
| Cho, HJ; Choi, CM; Choi, YD; Hur, JY; Kim, TO; Kim, YC; Lim, JH; Oh, IJ; Park, CK; Shin, HJ | 1 |
| Fukumoto, S; Harada, M; Kiuchi, S; Oizumi, S; Watanabe, M; Yamada, N; Yokouchi, H | 1 |
| Chong, IW; Hsu, JF; Huang, MS; Hung, JY; Lee, MH; Liu, TC; Tsai, MJ; Tsai, YC; Tsai, YM; Yang, CJ | 1 |
| Kastelijn, EA; Peters, BJM; Roepman, P; Schramel, FMNH; Sluga, R; VAN DEN Borne, BEEM | 1 |
| D'Alessandro-Gabazza, CN; Fujimoto, H; Fujiwara, A; Gabazza, EC; Hataji, O; Ito, K; Kobayashi, T; Nakahara, H; Nishihama, K; Taguchi, O; Yasuma, T; Yoshida, M | 1 |
| Albiol-Chiva, J; Esteve-Romero, J; Peris-Vicente, J | 1 |
| Kang, Y; Ma, W; Yang, L; Yang, T; Zhu, M | 1 |
| Cappuzzo, F; Cseh, A; Forman, ND; Hilbe, W; Hochmair, M; Jazieh, AR; Lam, KC; Linden, S; Lorence, RM; Schuler, M; Soo, R; Stehle, G; Tsai, CM | 1 |
| Komada, F | 1 |
| Baba, K; Hasegawa, Y; Ishioka, Y; Itoga, M; Nakagawa, H; Taima, K; Takanashi, S; Tanaka, H; Tanaka, Y; Tasaka, S | 1 |
| Furukawa, R; Matsumoto, Y; Ohara, S; Taniguchi, Y; Usui, K | 1 |
| Huo, X; Liu, K; Liu, Q; Liu, Z; Ma, X; Meng, Q; Sun, H; Sun, P; Wang, C; Yang, X; Zhang, Y | 1 |
| Hirashima, T; Iwata, K; Masuhiro, K; Morishita, N; Morita, S; Nasu, S; Okamoto, N; Ryota, N; Shiroyama, T; Suzuki, H; Takata, SO; Tanaka, A; Ueda, Y | 1 |
| Lee, VHF | 1 |
| Chan, RT | 1 |
| Miyoshi, S; Namba, K; Sakaguchi, M; Sato, H; Shien, K; Soh, J; Suzawa, K; Takeda, T; Tomida, S; Torigoe, H; Toyooka, S; Tsukuda, K; Yamamoto, H; Yoshioka, T | 1 |
| Dziadziuszko, R; Palczewski, P; Płatek, AE; Szymański, FM; Łęgosz, P | 1 |
| Borics, A; Dömötör, O; Enyedy, ÉA; Keppler, BK; Kowol, CR; Pelivan, K | 1 |
| Egger, J; Hann, A; Hermann, PC; Keller, F; Nosalski, E; Seufferlein, T | 1 |
| Altan, M; Brahmer, JR; Carter, BW; Chen, T; Doebele, RC; Elamin, YY; Estrada-Bernal, A; Goldberg, SB; Heymach, JV; Le, AT; Li, S; Liu, S; Lu, C; Nilsson, MB; Papadimitrakopoulou, V; Politi, K; Poteete, A; Roarty, E; Robichaux, JP; Sun, H; Tan, Z; Truini, A; Wong, KK; Zhang, S | 1 |
| Duchnowska, R; Jassem, J; Loibl, S | 1 |
| Burslem, K; Earnshaw, S; Graham, J; Lim, J | 1 |
| Chi, WM; Hsieh, WS; Hsu, KW; Huang, LC; Lee, AW; Lee, CH; Lin, CL; Lin, CY; Liu, WN; Tam, KW; Yang, JM | 1 |
| Alexandre, J; Allard, M; Arrondeau, J; Bellesoeur, A; Blanchet, B; Boudou-Rouquette, P; Chapron, J; Giraud, F; Goldwasser, F; Labat, L; Reis, R; Thomas-Schoemann, A; Vidal, M | 1 |
| Fujita, S; Fukushima, S; Imamichi, F; Irie, K; Katakami, N; Masago, K; Okada, Y; Yatabe, Y | 1 |
| Al Mamun Bhuyan, A; Lang, F | 1 |
| Bin, L; Guo-Qiang, LI; Liang, S; Yu-Hua, Z | 1 |
| Graziano, S; Sharma, N | 1 |
| Ishimoto, O; Kawashima, Y; Kikuchi, T; Kobayashi, K; Maeno, Y; Masumoto, AI; Nukiwa, T; Sugawara, S; Watanabe, S; Yamaguchi, OU; Yoshizawa, H | 1 |
| Charles Victor, J; Cheema, PK; Cheng, SY; Khanna, S; Leake, J; Thawer, A | 1 |
| Endo, T; Furukawa, K; Hayashihara, K; Hizawa, N; Ichimura, H; Inagaki, M; Kaburagi, T; Kikuchi, N; Kimura, M; Kurishima, K; Miyazaki, K; Nakamura, H; Nawa, T; Saito, K; Satoh, H; Tamura, T; Yamashita, T | 1 |
| Liu, S; Lv, X; Sun, K; Yang, X; Yin, J | 1 |
| Harada, T; Kawano, Y; Kimura, S; Liu, R; Nakanishi, Y; Okamoto, I; Shibahara, D; Tanaka, K | 1 |
| Chihara, Y; Hasegawa, I; Hiranuma, O; Hiraoka, N; Kaneko, Y; Kubota, Y; Shiotsu, S; Takayama, K; Takeda, T; Takumi, C; Tamiya, N; Tanimura, K; Uchino, J; Yamada, T; Yoshimura, A | 1 |
| Ikeuchi, T; Ishikawa, S; Tokuyasu, H | 1 |
| Brenner, JC; Carey, TE; Harris, M; Herbst, G; Jiang, H; Kulkarni, A; Leonard, E; Matovina, C; Michmerhuizen, NL; Zhai, J | 1 |
| Ando, C; Hara, N; Hirabae, A; Ichihara, E; Iwamoto, Y; Kiura, K; Maeda, Y; Nakasuka, T; Umeno, T | 1 |
| Jin, B; Liu, J; Liu, Y; Qu, X; Su, H | 1 |
| Clement, PM; Cohen, EEW; Cupissol, D; de Souza Viana, L; Fayette, J; Gauler, T; Geng, Y; Geoffrois, L; Guigay, J; Haddad, R; Keilholz, U; Kornek, G; Licitra, L; Machiels, JP; Melichar, B; Rauch, D; Ribaldo Nicolau, U; Rolland, F; Tahara, M; Vermorken, J; Zanetta-Devauges, S; Zografos, E | 1 |
| Harada, T; Inoue, S; Jingu, D; Nakagawa, T; Nakamura, A; Saito, R; Sugawara, S; Suzuki, A; Tanaka, H; Yamada, T | 1 |
| Chen, J; Fan, Y; Hua, H; Huang, DC; Shu, Y; Wang, H; Zhang, J; Zhou, C | 1 |
| Chen, M; Chen, W; Han, G; Jiang, Y; Mao, S; Shi, N; Yu, W; Zhang, X | 1 |
| Guo, Y; Ma, K; Qiu, S; Shao, J; Sun, C; Sun, M; Wang, X; Xu, Y | 1 |
| Chen, S; Li, S; Li, W; Wang, G; Wang, M; Wang, Q; Xia, J; Xu, Y; Zhang, D | 1 |
| Arnhof, H; Bader, G; Böttcher, J; Ettmayer, P; Gerstberger, T; Gmachl, M; Haering, D; Hauer, K; Hela, W; Hofmann, MH; Kennedy, MD; Kessler, D; Kofink, C; Kraut, N; Lamarre, L; McConnell, DB; Mendes, RL; Meyer, R; Munico-Martinez, S; O'Connell, JC; Pototschnig, N; Ramharter, J; Richard, D; Rumpel, K; Salamon, C; Sanderson, M; Schnitzer, R; Weiner, I; Werni, P; Wolkerstorfer, B; Wunberg, T; Zöphel, A | 1 |
| Bates, V; Boland, A; Chaplin, M; Dundar, Y; Green, JA; Greenhalgh, J; Vecchio, F | 1 |
| Cameron, MG; Kersten, C | 1 |
| Akiyama, M; Chiba, S; Hirano, K; Maemondo, M; Nagashima, H; Sato, H; Sugai, T; Utsumi, Y; Yakuwa, K | 1 |
| Lee, JY; Lin, CF; Liu, SY; Lo, TK; Su, PL | 1 |
| Du, X; Liu, W; Wang, Z; Xiong, X; Yang, L; Yang, P; Zhang, Y; Zhou, C | 1 |
| Akangunduz, B; Akdeniz, N; Aksoy, A; Akyol, M; Alan, Ö; Arak, H; Atci, MM; Balli, S; Bayram, E; Bekmez, ET; Bilgin, B; Bilici, A; Cavdar, E; Celik, E; Demirci, NS; Demirkazik, A; Ellez, Hİ; Erdem, D; Erdoğan, AP; Goker, E; Gursoy, P; Hedem, E; Katgi, N; Kilickap, S; Kut, E; Menekse, S; Nart, D; Oyan, B; Ozturk, A; Pilanci, KN; Sakalar, T; Sakin, A; Selçukbiricik, F; Tatli, AM; Telli, TA; Topcu, A; Turhal, S; Turkoz, FP; Yapar, B; Yildirim, HÇ; Yumuk, PF | 1 |
| Arteaga, CL; Bedard, PL; Chen, AP; Conley, BA; Flaherty, KT; Gray, RJ; Hamilton, SR; Harris, LN; Li, S; Limaye, SA; McShane, LM; Mitchell, EP; Moscow, JA; O'Dwyer, PJ; Patton, DR; Rubinstein, LV; Wang, V; Williams, PM; Wisinski, KB; Yang, ES; Zwiebel, JA | 1 |
| Fujita, M; Igata, F; Ikeuchi, N; Ito, K; Masutani, K; Morita, D; Murayama, H; Nakamura, T; Nishida, Y; Oda, T; Takahashi, K; Uesugi, N; Watanabe, M; Yasuno, T | 1 |
| Brueckl, WM; Ficker, JH; Griesinger, F; Kokowski, K; Krüger, S; Laack, E; Möller, M; Neben, K; Rawluk, J; Reck, M; Schäfer, H; Schueler, A | 1 |
| Hatakeyama, N; Ichihara, S; Kadota, N; Kunishige, M; Machida, H; Naruse, K; Okano, Y; Shinohara, T; Takeuchi, E | 1 |
96 review(s) available for quinazolines and bibw 2992
| Article | Year |
|---|---|
BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors.
Topics: Afatinib; Animals; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Drugs, Investigational; ErbB Receptors; Humans; Neoplasms; Quinazolines; Receptor, ErbB-2 | 2008 |
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Quinazolinones | 2009 |
Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.
Topics: Afatinib; Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Forecasting; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Morpholines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Trastuzumab; Up-Regulation | 2009 |
The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Morpholines; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Quinolines | 2010 |
EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Drug Discovery; Humans; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Quinazolines; Randomized Controlled Trials as Topic | 2010 |
BIBW 2992 in non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2011 |
The search for improved systemic therapy of non-small cell lung cancer--what are today's options?
Topics: Afatinib; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Precision Medicine; Protein-Tyrosine Kinases; Quinazolines; Quinolines | 2011 |
Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2012 |
New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms, Hormone-Dependent; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2012 |
An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents.
Topics: Afatinib; Aminoquinolines; Angiogenesis Inhibitors; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lapatinib; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Quinolines | 2013 |
Dermatologic adverse events associated with afatinib: an oral ErbB family blocker.
Topics: Administration, Oral; Afatinib; Alopecia; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Exanthema; Humans; Paronychia; Protein Kinase Inhibitors; Pruritus; Quinazolines; Receptor, ErbB-2 | 2013 |
Diarrhea associated with afatinib: an oral ErbB family blocker.
Topics: Administration, Oral; Afatinib; Diarrhea; ErbB Receptors; Humans; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4 | 2013 |
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2013 |
Clinical perspective of afatinib in non-small cell lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
Afatinib: first global approval.
Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Drug Approval; European Union; Humans; Lung; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Grading; Neoplasm Proteins; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Taiwan; United States; United States Food and Drug Administration | 2013 |
The role of afatinib in the management of non-small cell lung carcinoma.
Topics: Afatinib; Antineoplastic Agents; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2013 |
Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Polymorphism, Single Nucleotide; Quinazolines | 2013 |
A systematic review of dual targeting in HER2-positive breast cancer.
Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoadjuvant Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Up-Regulation | 2014 |
Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Evaluation, Preclinical; Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2013 |
[HER2-positive breast cancer: available targeted agents and biomarkers for therapy response].
Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Everolimus; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Quinolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab | 2013 |
Afatinib in the treatment of head and neck squamous cell carcinoma.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2014 |
Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Neoplasm Grading; Protein Kinase Inhibitors; Quinazolines | 2014 |
Subsequent treatment choices for patients with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI?
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Retreatment | 2014 |
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crown Ethers; Data Collection; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Markov Chains; Mutation; Probability; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.
Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2014 |
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.
Topics: Afatinib; Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; ErbB Receptors; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome | 2014 |
Afatinib for the treatment of advanced non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Factors | 2015 |
[Adverse events of afatinib as first-line treatment for five cases of advanced lung adenocarcinoma and review of literature].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Stomatitis | 2014 |
Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
Next generation tyrosine kinase inhibitor (TKI): afatinib.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Patents as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic | 2014 |
Management and future directions in non-small cell lung cancer with known activating mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Mutation Rate; Neoplasms, Squamous Cell; Oncogenes; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2014 |
Afatinib in the treatment of breast cancer.
Topics: Afatinib; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2014 |
[Afatinib (BIBW 2992)].
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Approval; ErbB Receptors; France; Humans; Lung Neoplasms; Quinazolines | 2014 |
Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Proportional Hazards Models; Quinazolines | 2014 |
Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel.
Topics: Afatinib; Antineoplastic Agents; Diarrhea; Disease Management; Exanthema; Humans; Mucositis; Neoplasms; Paronychia; Practice Guidelines as Topic; Quinazolines; Spain; Stomatitis | 2015 |
Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2014 |
Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Models, Biological; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2015 |
Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines | 2014 |
Afatinib and lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Lung Neoplasms; Quinazolines | 2014 |
Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.
Topics: Afatinib; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Signal Transduction; Survival Rate | 2015 |
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2015 |
[Pharmacological and clinical profile of afatinib (Giotrif®)].
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Dose-Response Relationship, Drug; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quinazolines | 2015 |
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Publication Bias; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk | 2015 |
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Research Progress in Head and Neck Squamous Cell Carcinoma: Best Abstracts of ICHNO 2015.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Squamous Cell; Early Detection of Cancer; Head and Neck Neoplasms; Humans; Immunotherapy; Meta-Analysis as Topic; Methotrexate; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Papillomavirus Vaccines; Postoperative Care; Precision Medicine; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Squamous Cell Carcinoma of Head and Neck; Therapies, Investigational | 2015 |
Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical Surgeon.
Topics: Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2015 |
Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2015 |
Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2016 |
Renal toxicity of anticancer agents targeting HER2 and EGFR.
Topics: Acute Kidney Injury; Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Maytansine; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Renal Dialysis; Renal Insufficiency, Chronic; Trastuzumab | 2015 |
Managing acquired resistance in EGFR-mutated non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2015 |
Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2015 |
Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis.
Topics: Afatinib; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotransferases; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2016 |
Pyogenic granuloma caused by afatinib: Case report and review of the literature.
Topics: Afatinib; Aged; Antineoplastic Agents; Female; Fingers; Granuloma, Pyogenic; Hand Dermatoses; Humans; Quinazolines | 2017 |
Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Humans; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2016 |
Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.
Topics: Afatinib; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Genotype; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2016 |
Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature.
Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2016 |
Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Rate | 2016 |
Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azepines; Carcinoma, Squamous Cell; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinazolinones; Signal Transduction; Sirolimus | 2016 |
Afatinib in squamous cell carcinoma of the head and neck.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Disease-Free Survival; Head and Neck Neoplasms; Humans; Maximum Tolerated Dose; Methotrexate; Neoplasm Recurrence, Local; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2016 |
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2016 |
Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer.
Topics: Afatinib; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; ErbB Receptors; Humans; Quinazolines; Vascular Endothelial Growth Factors | 2016 |
Kinases inhibitors in lung cancer: From benchside to bedside.
Topics: Afatinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines | 2016 |
[Current status of EGFR/ErbB inhibitors in non-small cell lung carcinoma].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-2; Genetic Markers; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2016 |
[Mechanism of action and preclinical development of afatinib].
Topics: Afatinib; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; Treatment Outcome | 2016 |
[Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].
Topics: Afatinib; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Genes, erbB; Genetic Markers; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
[Evidence on afatinib in patients progressing on a first-line treatment].
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Administration Schedule; ErbB Receptors; Genes, erbB; Genetic Markers; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
[Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
Topics: Administration, Oral; Afatinib; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Genes, erbB; Genetic Markers; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
[Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib].
Topics: Afatinib; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Genes, erbB; Genetic Markers; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.
Topics: Afatinib; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Interactions; ErbB Receptors; Humans; Kidney; Liver; Neoplasms; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents | 2017 |
The safety of afatinib for the treatment of non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quality of Life; Quinazolines; Risk Factors | 2016 |
Afatinib: A Review in Advanced Non-Small Cell Lung Cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2016 |
Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm.
Topics: Acrylamides; Adenocarcinoma; Afatinib; Amino Acid Substitution; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2017 |
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Rate | 2017 |
Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2017 |
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Lung Neoplasms; Mutation; Outcome Assessment, Health Care; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2017 |
Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome | 2017 |
Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Disease-Free Survival; Drug Approval; Endpoint Determination; Humans; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Sulfones | 2017 |
Recent Management of Patients with Advanced Epidermal Growth Factor Receptor Mutation Non-small Cell Lung Cancer: Role of Afatinib and Lesson Learned for Developing Countries.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Developing Countries; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Indonesia; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2017 |
Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crown Ethers; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Network Meta-Analysis; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.
Topics: Afatinib; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Ramucirumab; Retreatment; Taxoids | 2017 |
Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2017 |
Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines | 2017 |
Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2018 |
Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review
.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kidney Failure, Chronic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines; Renal Dialysis; Taxoids | 2018 |
Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer.
Topics: Afatinib; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Receptor, ErbB-2 | 2018 |
Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Prognosis; Quinazolines; Radiation-Sensitizing Agents | 2018 |
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Topics: Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bias; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Progression-Free Survival; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2021 |
85 trial(s) available for quinazolines and bibw 2992
| Article | Year |
|---|---|
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours.
Topics: Adolescent; Adult; Afatinib; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Keratinocytes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Receptor, ErbB-2; Skin; Time Factors; Tissue Distribution; Treatment Outcome | 2008 |
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.
Topics: Adult; Afatinib; Aged; Drug Administration Schedule; ErbB Receptors; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2010 |
The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Humans; Indoles; Male; Middle Aged; Quinazolines; Survival Rate | 2011 |
Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers.
Topics: Administration, Oral; Adult; Afatinib; Carbon Radioisotopes; ErbB Receptors; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2012 |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.
Topics: Adenocarcinoma; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2012 |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Female; Humans; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis; Treatment Outcome | 2012 |
Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Skin Diseases; Taxoids | 2013 |
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.
Topics: Afatinib; Aged; Aged, 80 and over; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Quinazolines; Tissue Distribution | 2013 |
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Afatinib; Aged; Aged, 80 and over; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Quinazolines; Tissue Distribution | 2013 |
A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Quinazolines | 2013 |
Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Fatigue; Female; Follow-Up Studies; Gefitinib; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain; Prognosis; Quality of Life; Quinazolines; Salvage Therapy | 2013 |
Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; ErbB Receptors; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Quinazolines; Taxoids; Treatment Outcome | 2013 |
Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; ErbB Receptors; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Neoplasms; Prospective Studies; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2013 |
Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours.
Topics: Adolescent; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Young Adult | 2013 |
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; ErbB Receptors; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pemetrexed; Quinazolines | 2013 |
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2013 |
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Pemetrexed; Quality of Life; Quinazolines; Treatment Outcome | 2013 |
Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors.
Topics: Administration, Oral; Afatinib; Aged; Antineoplastic Agents; Electrocardiography; ErbB Receptors; Female; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2013 |
Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir.
Topics: Adolescent; Adult; Afatinib; Cross-Over Studies; Drug Combinations; Drug Interactions; Humans; Male; Middle Aged; Quinazolines; Rifampin; Ritonavir; Young Adult | 2014 |
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Risk Factors; Thailand; Time Factors; Treatment Outcome | 2014 |
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.
Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Indoles; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Treatment Outcome | 2014 |
LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Quinazolines; Treatment Outcome | 2014 |
Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFR.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Republic of Korea | 2014 |
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
Topics: Adolescent; Adult; Afatinib; Aged; Area Under Curve; Case-Control Studies; Female; Follow-Up Studies; Humans; Liver Diseases; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Quinazolines; Receptor, ErbB-2; Tissue Distribution; Young Adult | 2014 |
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines; Receptor, ErbB-2; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Young Adult | 2014 |
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Protocols; Disease Progression; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Retreatment; Squamous Cell Carcinoma of Head and Neck | 2014 |
A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pemetrexed; Quinazolines; Response Evaluation Criteria in Solid Tumors | 2014 |
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Temozolomide; Treatment Outcome | 2015 |
Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib.
Topics: Adenocarcinoma; Afatinib; Disease-Free Survival; Health Status; Humans; Longitudinal Studies; Lung Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2014 |
Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Retreatment; Trastuzumab | 2015 |
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized control
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Protocols; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Head and Neck Neoplasms; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Research Design; Risk Factors; Squamous Cell Carcinoma of Head and Neck; Time Factors; Treatment Outcome | 2014 |
A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Afatinib; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cecal Neoplasms; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2014 |
Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Genes, erbB-1; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2015 |
A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Prognosis; Quinazolines; Survival Rate | 2015 |
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2015 |
Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).
Topics: Adult; Afatinib; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Middle Aged; Neoadjuvant Therapy; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2015 |
Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pre-Exposure Prophylaxis; Quinazolines; Risk Factors; Skin Diseases; Tetracycline | 2015 |
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2015 |
Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quality of Life; Quinazolines; Treatment Outcome | 2015 |
A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Staging; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Quinazolines | 2015 |
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome; Tumor Burden | 2015 |
Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer.
Topics: Afatinib; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Female; Gastrointestinal Diseases; Humans; Lung Neoplasms; Male; Nutritional Status; Quinazolines | 2015 |
Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Dose-Response Relationship, Drug; Drug Monitoring; ErbB Receptors; Female; Humans; Japan; Leukopenia; Male; Middle Aged; Neoplasms; Patient Dropouts; Protein Kinase Inhibitors; Quinazolines; Tumor Burden; Vinblastine; Vinorelbine | 2015 |
A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Topics: Administration, Intravenous; Administration, Oral; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; ErbB Receptors; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Time Factors; Treatment Outcome; United Kingdom | 2015 |
A phase I study of volasertib combined with afatinib, in advanced solid tumors.
Topics: Administration, Oral; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Infusions, Intravenous; Male; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Neutropenia; Protein Kinase Inhibitors; Pteridines; Quinazolines; Severity of Illness Index; Thrombocytopenia | 2015 |
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Biopsy; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Male; Middle Aged; Mutation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines | 2016 |
Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2015 |
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 tr
Topics: Adult; Afatinib; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Canada; Disease Progression; Disease-Free Survival; Europe; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Republic of Korea; Risk Factors; Time Factors; Trastuzumab; Treatment Outcome; United States; Vinblastine; Vinorelbine | 2015 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2016 |
A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.
Topics: Adult; Afatinib; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents | 2016 |
A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.
Topics: Afatinib; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Quinazolines; Treatment Outcome | 2016 |
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Risk Assessment; Survival Analysis; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Quinazolines; Treatment Outcome | 2016 |
Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erloti
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2016 |
Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Disease-Free Survival; Female; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Radiation-Sensitizing Agents; Treatment Outcome | 2016 |
Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Urologic Neoplasms; Urothelium | 2016 |
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.
Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2016 |
Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Young Adult | 2017 |
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Republic of Korea | 2016 |
A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Quinazolines | 2017 |
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.
Topics: Adolescent; Adult; Afatinib; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Quinazolines; Receptor, ErbB-2; Vinblastine; Vinorelbine; Young Adult | 2016 |
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Chemical Analysis; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Quinazolines | 2017 |
Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Retreatment; Simvastatin; Survival Analysis; Treatment Outcome | 2017 |
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Quinazolines; Treatment Outcome | 2017 |
Evaluation of the VeriStrat
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Hematologic Tests; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Quinazolines; Retrospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Analysis; Treatment Outcome | 2017 |
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Monitoring; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retreatment; Sirolimus; Treatment Outcome | 2017 |
Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Humans; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
Topics: Administration, Intravenous; Administration, Oral; Afatinib; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous Cell; Disease-Free Survival; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Predictive Value of Tests; Quinazolines; Squamous Cell Carcinoma of Head and Neck | 2017 |
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cohort Studies; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2017 |
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6).
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Health Status; Humans; Lung Neoplasms; Male; Patient Reported Outcome Measures; Polymorphism, Single Nucleotide; Quality of Life; Quinazolines; Survival Analysis | 2018 |
A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations.
Topics: Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Mutation; Prognosis; Quinazolines; Survival Rate | 2018 |
Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Young Adult | 2018 |
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Neoplasm Recurrence, Local; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Adherence and Compliance; Treatment Outcome | 2019 |
Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601).
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Japan; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2020 |
Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome | 2020 |
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.
Topics: Afatinib; Breast Neoplasms; Diarrhea; Female; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Mutation; National Cancer Institute (U.S.); Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Stroke Volume; United States; Ventricular Function, Left | 2022 |
309 other study(ies) available for quinazolines and bibw 2992
| Article | Year |
|---|---|
Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma.
Topics: Administration, Oral; Afatinib; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Flow Cytometry; Humans; Hypopharyngeal Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Transplantation, Heterologous; Tumor Stem Cell Assay | 2007 |
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Disease Models, Animal; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mice, Transgenic; NIH 3T3 Cells; Phosphorylation; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Afatinib; Aged; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Protein Structure, Quaternary; Quinazolines; Sequence Alignment | 2008 |
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Lung Neoplasms; Mice; Mutation; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Sirolimus | 2009 |
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.
Topics: Afatinib; Amphiregulin; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Disease Models, Animal; Drug Resistance, Neoplasm; EGF Family of Proteins; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Mice; Mice, Nude; Mice, Transgenic; Mutation; Neoplasm Transplantation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 2009 |
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.
Topics: Afatinib; Amino Acid Substitution; Animals; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Furans; Humans; Lung Neoplasms; Molecular Structure; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2010 |
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Topics: Afatinib; Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; E2F1 Transcription Factor; ErbB Receptors; Fluorouracil; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mice; Mutation; Oxonic Acid; Pemetrexed; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Mas; Quinazolines; Tegafur; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2010 |
Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members.
Topics: Afatinib; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Oncogene Proteins v-erbB; Quinazolines | 2011 |
Afatinib (BIBW 2992) development in non-small-cell lung cancer.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2011 |
EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.
Topics: Afatinib; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Proliferation; Cell Survival; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; HT29 Cells; Humans; Indoles; Mice; Mice, Nude; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells.
Topics: Afatinib; Animals; Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Division; Cell Line, Tumor; Colorimetry; Drug Screening Assays, Antitumor; Humans; Mice; Oncogene Proteins v-erbB; Pancreatic Neoplasms; Quinazolines; Xenograft Model Antitumor Assays | 2011 |
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2012 |
The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.
Topics: Adenocarcinoma; Adult; Afatinib; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy.
Topics: Afatinib; Antineoplastic Agents; Catalytic Domain; Crystallography, X-Ray; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Models, Molecular; Molecular Targeted Therapy; Mutation, Missense; Neoplasms; Protein Binding; Protein Structure, Secondary; Quinazolines; Quinolines | 2012 |
Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.
Topics: Adenocarcinoma; Afatinib; Aged; Amino Acid Sequence; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Prognosis; Protein Kinases; Quinazolines; Receptor, ErbB-2; Sequence Homology, Amino Acid | 2012 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cetuximab; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Phenotype; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering; Transfection | 2012 |
A new generation of EGFR tyrosine-kinase inhibitors in NSCLC.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2012 |
The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials.
Topics: Adenocarcinoma, Papillary; Adult; Afatinib; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Ovarian Neoplasms; Paclitaxel; Pelvic Neoplasms; Phthalazines; Piperazines; Quinazolines; Uterine Cervical Neoplasms | 2012 |
Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dideoxynucleosides; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Quinazolines; Radionuclide Imaging; Radiopharmaceuticals; Sequence Deletion | 2012 |
Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.
Topics: Afatinib; Animals; Cell Proliferation; Cells, Cultured; Crystallography; Data Interpretation, Statistical; ErbB Receptors; Genes, erbB; Humans; Mice; Models, Molecular; Molecular Sequence Data; Phosphorylation; Phosphotransferases; Protein Conformation; Proto-Oncogene Mas; Quinazolines; Receptor, ErbB-2; Spectrum Analysis; Structure-Activity Relationship; Surface Plasmon Resonance; Transfection | 2012 |
Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Topics: Afatinib; Animals; Autocrine Communication; Carcinoma, Non-Small-Cell Lung; Cell Communication; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblasts; Humans; Interleukin-6; Janus Kinase 1; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Receptors, Interleukin-6; Signal Transduction; STAT3 Transcription Factor; Stromal Cells; Xenograft Model Antitumor Assays | 2012 |
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering | 2012 |
Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Transcription Factors | 2012 |
Epidermal growth factor receptor (EGFR) inhibitors and derived treatments.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Quinazolines; Quinolines; Translational Research, Biomedical; Treatment Outcome | 2012 |
Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma.
Topics: Afatinib; Animals; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; DNA Breaks; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; ErbB Receptors; G1 Phase; Humans; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Phosphorylation; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy; Random Allocation; Receptor, ErbB-2; Signal Transduction; Urinary Bladder Neoplasms | 2013 |
Disseminated herpes simplex virus infection following epidermal growth factor tyrosine kinase inhibitor therapy for non-small-cell lung carcinoma.
Topics: Acyclovir; Afatinib; Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Non-Small-Cell Lung; Cystitis; ErbB Receptors; Esophagitis; Hematuria; Herpes Simplex; Humans; Intestinal Perforation; Lung Neoplasms; Male; Molecular Targeted Therapy; Neoplasm Proteins; Peritonitis; Protein Kinase Inhibitors; Quinazolines; Valacyclovir; Valine; Viremia; Virus Activation | 2012 |
Strides in personalized medicine.
Topics: Afatinib; Gastrointestinal Stromal Tumors; Humans; Lung Neoplasms; Melanoma; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins B-raf; Pyridines; Quinazolines | 2012 |
Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Gene Targeting; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering | 2013 |
Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells.
Topics: Afatinib; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Humans; Pancreatic Neoplasms; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-3; Receptor, IGF Type 1 | 2013 |
Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.
Topics: Afatinib; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; MCF-7 Cells; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Treatment Outcome | 2013 |
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
Topics: Afatinib; Antibiotics, Antineoplastic; Cell Line, Tumor; ErbB Receptors; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lapatinib; Loss of Heterozygosity; Naphthyridines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Quinazolines; Resorcinols; Signal Transduction; Sirolimus; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein; Tumor Cells, Cultured; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2013 |
[About new treatments in thoracic oncology].
Topics: Afatinib; Antineoplastic Agents; Crizotinib; DNA Mutational Analysis; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Oncogene Proteins, Fusion; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines | 2013 |
Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model.
Topics: Afatinib; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; ErbB Receptors; Exons; Female; Gefitinib; Heterografts; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2013 |
Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
Topics: Afatinib; Analysis of Variance; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorometry; Gefitinib; Humans; Indoles; Microscopy, Fluorescence; Piperazines; Proto-Oncogene Proteins c-met; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Signal Transduction; Spectrophotometry; Sulfonamides | 2013 |
Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.
Topics: Afatinib; Animals; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cell Transformation, Neoplastic; Fluorodeoxyglucose F18; Humans; Mice; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Radiochemistry; Receptor, ErbB-2; Stomach Neoplasms; Treatment Outcome | 2013 |
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; France; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutagenesis, Insertional; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Spain; Switzerland; Trastuzumab; Treatment Outcome | 2013 |
EGFR: tale of the C-terminal tail.
Topics: Afatinib; Animals; ErbB Receptors; Humans; Models, Molecular; Peptide Fragments; Protein Conformation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Genetic and chemical targeting of epithelial-restricted with serine box reduces EGF receptor and potentiates the efficacy of afatinib.
Topics: Afatinib; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; DNA-Binding Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Heterografts; Humans; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ets; Quinazolines; Receptor, ErbB-2; Squamous Cell Carcinoma of Head and Neck; Transcription Factors | 2013 |
A gene expression profile indicative of early stage HER2 targeted therapy response.
Topics: Afatinib; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2; Time Factors | 2013 |
Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation.
Topics: Afatinib; AMP-Activated Protein Kinases; Carcinoma, Non-Small-Cell Lung; Deoxyglucose; Drug Resistance, Neoplasm; ErbB Receptors; Glycolysis; Humans; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Protein Biosynthesis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2013 |
New kinase inhibitor approved for metastatic lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Quinazolines | 2013 |
Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2013 |
Irreversible kinase inhibitors gain traction.
Topics: Afatinib; Antineoplastic Agents; Drug Approval; Drug Design; Drug Industry; Humans; Protein Kinase Inhibitors; Quinazolines; United States; United States Food and Drug Administration | 2013 |
Evidence from mouse and man for a role of neuregulin 3 in nicotine dependence.
Topics: Adolescent; Adult; Afatinib; Aged; Animals; Behavior, Animal; Cyclic AMP Response Element-Binding Protein; DNA; Female; Genetic Predisposition to Disease; Genome-Wide Association Study; Hippocampus; Humans; Intracellular Signaling Peptides and Proteins; Male; Mice; Middle Aged; Mutation; Neuregulins; Nicotine; Polymorphism, Single Nucleotide; Quinazolines; Rats; Receptor, ErbB-4; Smoking; Substance Withdrawal Syndrome; Tobacco Use Cessation Devices; Tobacco Use Disorder; White People; Young Adult | 2014 |
Afatinib monotherapy in EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Afatinib; Clinical Trials, Phase III as Topic; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.
Topics: Afatinib; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Gene Amplification; Gene Rearrangement; Humans; Lung Neoplasms; Microarray Analysis; Mutation; Oncogene Proteins, Fusion; Phosphorylation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2014 |
Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck.
Topics: Afatinib; Animals; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Oncogene Proteins v-erbB; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2014 |
The current state of molecularly targeted drugs targeting HGF/Met.
Topics: Acrylamides; Afatinib; Aminopyridines; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrrolidinones; Quinazolines; Quinolines; Signal Transduction; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
[Tumor microenvironment elicits primary resistance to afatinib through HGF secretion].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Coculture Techniques; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Fibroblasts; Hepatocyte Growth Factor; Humans; Lung; Lung Neoplasms; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Transforming Growth Factor alpha; Tumor Microenvironment; Vimentin | 2013 |
Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.
Topics: Acrylamides; Afatinib; Amino Acid Substitution; Animals; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation, Missense; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Afatinib for lung cancer: let there be light?
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin αvβ6 and maintained through TGFβ signalling.
Topics: Afatinib; Antigens, Neoplasm; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Adhesion Molecules; Coculture Techniques; Epithelial Cell Adhesion Molecule; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Integrins; Neoplasm Proteins; Quinazolines; Signal Transduction; Stromal Cells; Transforming Growth Factor beta | 2015 |
Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2014 |
Afatinib-related nonhematologic adverse events: is common evaluation enough for now?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2014 |
Reply to F. De Marinis et al.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2014 |
Reply to E.R. Haspinger et al.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2014 |
Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors.
Topics: Absorption; Adult; Afatinib; Aged; Aged, 80 and over; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2014 |
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines | 2013 |
[Acquired trichomegaly and hypertrichosis].
Topics: Afatinib; Aged, 80 and over; Eyelashes; Female; Humans; Hypertrichosis; Quinazolines | 2014 |
A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.
Topics: Afatinib; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; ErbB Receptors; Glioma; Humans; Inhibitory Concentration 50; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-met; Pyridazines; Pyridones; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Stomach Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
HER2 aberrations in cancer: implications for therapy.
Topics: Ado-Trastuzumab Emtansine; Adult; Afatinib; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; Maytansine; Molecular Targeted Therapy; Mutation; Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Up-Regulation; Uterine Cervical Neoplasms | 2014 |
Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Time Factors; Treatment Outcome; United Kingdom | 2014 |
Afatinib, a lung cancer inhibitor of ErbB family.
Topics: Afatinib; Animals; Antineoplastic Agents; ErbB Receptors; Humans; Neoplasms; Quinazolines | 2014 |
New protein kinase inhibitors in breast cancer: afatinib and neratinib.
Topics: Afatinib; Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2 | 2014 |
Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Mice, Transgenic; Multiprotein Complexes; Mutation; Quinazolines; Random Allocation; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
A rapid ex vivo tissue model for optimising drug detection and ionisation in MALDI imaging studies.
Topics: Administration, Intravenous; Administration, Oral; Afatinib; Animals; Camptothecin; Erlotinib Hydrochloride; In Vitro Techniques; Irinotecan; Liver; Mice; Mice, Inbred C57BL; Mice, Nude; Models, Animal; Molecular Structure; Pyridones; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; ErbB Receptors; Female; Humans; Li-Fraumeni Syndrome; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2 | 2014 |
Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines | 2014 |
Ten lessons from EGFR.
Topics: Afatinib; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines | 2014 |
Afatinib with concurrent radiotherapy in a patient with metastatic non-small cell lung cancer.
Topics: Afatinib; Aged; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Lung Neoplasms; Quinazolines; Radiotherapy, Conformal; Treatment Outcome | 2014 |
Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Quinazolines; Renal Dialysis | 2014 |
Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo.
Topics: Adult; Afatinib; Aged; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Drug Compounding; Female; Hep G2 Cells; Humans; Immunoblotting; Male; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Micelles; Middle Aged; Polymers; Quinazolines; Receptor, ErbB-2; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis.
Topics: Afatinib; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Feeding Behavior; Gefitinib; Humans; Incidence; Lung Neoplasms; Mucositis; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Withholding Treatment | 2014 |
Afatinib enhances the efficacy of conventional chemotherapeutic agents by eradicating cancer stem-like cells.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; DNA Methylation; Drug Synergism; Humans; Leukemia; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplastic Stem Cells; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Signal Transduction; Topotecan; Xenograft Model Antitumor Assays | 2014 |
[A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Consensus; Drug Administration Schedule; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4 | 2014 |
Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain; Cetuximab; ErbB Receptors; Fatal Outcome; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Meningeal Neoplasms; Mutation; Neoplasms, Second Primary; Quinazolines | 2014 |
Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors.
Topics: Afatinib; Animals; Cell Line, Tumor; ErbB Receptors; Fluorine Radioisotopes; Isotope Labeling; Metabolic Clearance Rate; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Organ Specificity; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution | 2014 |
FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mutation; Nuclear Proteins; Oncogene Protein v-akt; Protein Kinase Inhibitors; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Transfection; Twist-Related Protein 1 | 2014 |
β-catenin contributes to lung tumor development induced by EGFR mutations.
Topics: Afatinib; Animals; Antineoplastic Agents; beta Catenin; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Doxycycline; ErbB Receptors; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Lung Neoplasms; Mice, Transgenic; Mutation, Missense; Protein Stability; Quinazolines; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Compassionate Use Trials; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2014 |
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome | 2014 |
Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.
Topics: Adult; Afatinib; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Novel approach of MALDI drug imaging, immunohistochemistry, and digital image analysis for drug distribution studies in tissues.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Immunohistochemistry; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Sarcoma; Sorafenib; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution | 2014 |
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Animals; Apoptosis; Cell Cycle; Cell Proliferation; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; In Vitro Techniques; Mice; Mice, SCID; Middle Aged; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Comparative Genomic Hybridization; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Variation; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Phosphatidylinositol 3-Kinases; Polymerase Chain Reaction; Proteomics; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2015 |
The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer.
Topics: Acrylamides; Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Caspases; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Lung Neoplasms; Mice; Mutation; Neoplasm Transplantation; Pyrimidines; Quinazolines; Vorinostat; Xenograft Model Antitumor Assays | 2015 |
New therapy targets resistant non-small-cell lung cancers.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Drug Combinations; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; National Cancer Institute (U.S.); Quinazolines; United States | 2014 |
Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.
Topics: Afatinib; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Immunohistochemistry; In Vitro Techniques; Male; Mice; Mice, Inbred BALB C; Neoplasm Proteins; Neoplasms, Experimental; Quinazolines; Real-Time Polymerase Chain Reaction; Topotecan; Xenograft Model Antitumor Assays | 2014 |
Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts.
Topics: Afatinib; Animals; Cell Line, Tumor; Chemoradiotherapy; Dose Fractionation, Radiation; ErbB Receptors; Female; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Quinazolines; Radiation-Sensitizing Agents; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2014 |
Synergistic cytotoxicity of afatinib and cetuximab against EGFR T790M involves Rab11-dependent EGFR recycling.
Topics: Afatinib; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Membrane; Cetuximab; Chlorocebus aethiops; COS Cells; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; HeLa Cells; Humans; K562 Cells; Membrane Proteins; Microscopy, Confocal; Microscopy, Fluorescence; Mutation; Proto-Oncogene Proteins; Quinazolines; rab GTP-Binding Proteins | 2014 |
Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.
Topics: Acrylamides; Afatinib; Aged; Aniline Compounds; Animals; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Male; Mice, Nude; Molecular Targeted Therapy; Mutation; Quinazolines | 2015 |
The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib.
Topics: Adenine; Afatinib; Animals; Area Under Curve; Cytosol; Dogs; Glutathione; Hepatocytes; Humans; Kidney; Liver; Macaca fascicularis; Male; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Quinolines; Rats | 2015 |
Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib.
Topics: Afatinib; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; ErbB Receptors; Exons; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Mutation; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2; Receptor, ErbB-3 | 2015 |
[Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Pemetrexed; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A.
Topics: Afatinib; Aged; Animals; Apoptosis; Autoantigens; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; ets-Domain Protein Elk-1; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Lung Neoplasms; Male; Membrane Proteins; Mice, Nude; Middle Aged; Mutation; Promoter Regions, Genetic; Protein Binding; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Xenograft Model Antitumor Assays | 2015 |
[Effect of EGFR-TKI on lymphangiogenesis of lung cancer with EGFR mutation].
Topics: Afatinib; Animals; Cell Line, Tumor; ErbB Receptors; Female; Humans; Lung Neoplasms; Lymphangiogenesis; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).
Topics: Afatinib; Aged; Aged, 80 and over; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoblotting; Immunohistochemistry; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Thiourea | 2015 |
Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2015 |
LUX-Lung: determining the best EGFR inhibitor in NSCLC?
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2015 |
Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells.
Topics: Afatinib; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA Damage; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptor, ErbB-2; Signal Transduction; Urinary Bladder Neoplasms | 2015 |
CD133-Positive Cells from Non-Small Cell Lung Cancer Show Distinct Sensitivity to Cisplatin and Afatinib.
Topics: AC133 Antigen; Afatinib; Antigens, CD; Antigens, Neoplasm; Carcinoma, Non-Small-Cell Lung; Cell Adhesion Molecules; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Epithelial Cell Adhesion Molecule; ErbB Receptors; Glycoproteins; Humans; Lung Neoplasms; Neoplastic Stem Cells; Peptides; Quinazolines | 2015 |
Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer.
Topics: Afatinib; Animals; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; ErbB Receptors; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Morpholines; Mucin-4; Pancreatic Neoplasms; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; STAT1 Transcription Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Long progression-free survival with afatinib in a patient with EGFR-unknown lung adenocarcinoma after erlotinib failure: a case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines; Treatment Failure; Treatment Outcome | 2015 |
Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation.
Topics: Afatinib; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Quinazolines; Radiation-Sensitizing Agents; Random Allocation; Xenograft Model Antitumor Assays | 2015 |
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Recurrence; Retinoblastoma Protein; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides | 2015 |
Synthesis, reactivity, and biological activity of gold(I) complexes modified with thiourea-functionalized tyrosine kinase inhibitors.
Topics: Afatinib; Cell Line; Cell Line, Tumor; Cell Proliferation; Coordination Complexes; Dose-Response Relationship, Drug; Gefitinib; Gold; Humans; Inhibitory Concentration 50; Protein Kinase Inhibitors; Quinazolines; Thiourea | 2015 |
Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor--Mutated Non--Small-Cell Lung Cancer With T790M Mutations.
Topics: Afatinib; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Panitumumab; Quinazolines | 2015 |
Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; HEK293 Cells; Humans; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2015 |
Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway.
Topics: 6-Aminonicotinamide; Afatinib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Glucose; Humans; Metabolome; Multiple Myeloma; Oxygen; Pentose Phosphate Pathway; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; ras Proteins; Receptor, ErbB-2; RNA, Small Interfering; TOR Serine-Threonine Kinases | 2015 |
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.
Topics: Acrylamides; Afatinib; Amino Acid Substitution; Animals; Cell Line, Tumor; Cell Proliferation; Codon; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Inhibitory Concentration 50; Mice; Models, Molecular; Molecular Conformation; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2015 |
[Hange-Shashin-to for preventing diarrhea during afatinib therapy].
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drugs, Chinese Herbal; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2015 |
Afatinib (Gilotrif) for advanced non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; United States; United States Food and Drug Administration | 2015 |
Successful Afatinib Therapy after Resistance to EGFR-TKI in a Patient with Advanced Adenosquamous Cell Lung Cancer.
Topics: Afatinib; Aged; Carcinoma, Adenosquamous; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lung Neoplasms; Mice; Mutation; Pyrazines; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
IBC as a Rapidly Spreading Systemic Disease: Clinical and Targeted Approaches Using the Neoadjuvant Model.
Topics: Afatinib; Antibodies, Monoclonal; Bevacizumab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Inflammatory Breast Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Outcome Assessment, Health Care; Panitumumab; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Remission Induction; Survival Analysis; Trastuzumab | 2015 |
[Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
Topics: Adenocarcinoma; Afatinib; Anaplastic Lymphoma Kinase; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2015 |
Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Quinazolinones; Signal Transduction; Up-Regulation | 2015 |
Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Exons; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Pemetrexed; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vinblastine; Vinorelbine | 2015 |
Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report.
Topics: Afatinib; Carcinoma, Large Cell; Cell Differentiation; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Quinazolines | 2015 |
Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib.
Topics: Afatinib; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Crizotinib; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Mutation; Neoplastic Stem Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Retinal Dehydrogenase; Sequence Analysis, DNA; Taxoids | 2015 |
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.
Topics: Afatinib; Animals; Cell Line, Tumor; Databases, Genetic; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gene Expression; Gene Frequency; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Models, Molecular; Molecular Conformation; Mutation; Mutation Rate; Protein Kinase Inhibitors; Quinazolines; Quinolines; Structure-Activity Relationship; Transfection; Treatment Outcome | 2015 |
miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma.
Topics: Afatinib; Animals; Antineoplastic Agents; Base Sequence; Carcinogenesis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding Proteins; ErbB Receptors; Gene Expression; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Lapatinib; Mice, Nude; MicroRNAs; Neoplasm Transplantation; Proto-Oncogene Proteins c-ets; Quinazolines; RNA Interference; Signal Transduction; Transcription Factors; Tumor Burden | 2015 |
Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment.
Topics: Afatinib; Breast Neoplasms; Cell Line, Tumor; Chromatography, Liquid; Female; Humans; Lapatinib; Mass Spectrometry; Protein Kinase Inhibitors; Proteomics; Quinazolines; Quinolines; Receptor, ErbB-2 | 2015 |
HER2 activating mutations are targets for colorectal cancer treatment.
Topics: Afatinib; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cell Transformation, Neoplastic; Colorectal Neoplasms; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Humans; Molecular Targeted Therapy; Mucous Membrane; Mutation; Quinazolines; Quinolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2015 |
EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.
Topics: Adult; Afatinib; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Gene Duplication; Gene Frequency; Humans; Lung Neoplasms; Male; Models, Molecular; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Protein Conformation; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Gastrointestinal Neoplasms; Gene Amplification; Gene Expression; Gene Knockdown Techniques; Humans; Lapatinib; Mice; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors.
Topics: Afatinib; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2015 |
Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1.
Topics: Afatinib; Amino Acid Sequence; Animals; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Sequence Data; Molecular Structure; NF-kappa B; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sequence Homology, Amino Acid; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
[Retrospective Analysis of the Afatinib Clinical Pathway during the 28-Day Introductory Period-The Japanese Style of Collaborative Drug Therapy Management(J-CDTM)].
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Exanthema; Female; Humans; Lung Neoplasms; Male; Medication Therapy Management; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Cell Line, Tumor; Cetuximab; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines | 2016 |
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Compassionate Use Trials; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2015 |
Functionalized gold nanoparticles improve afatinib delivery into cancer cells.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Gold; Humans; Inhibitory Concentration 50; Nanoparticles; Pancreatic Neoplasms; Polyethylene Glycols; Protein-Tyrosine Kinases; Quinazolines | 2016 |
Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Disease-Free Survival; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Markov Chains; Models, Economic; Molecular Targeted Therapy; Mutation; Patient Selection; Pemetrexed; Protein Kinase Inhibitors; Quality of Life; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Uncertainty; United States | 2015 |
The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Ligands; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neuregulin-1; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Topics: Afatinib; Brain Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; ErbB Receptors; Female; Genotype; Glioblastoma; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Proteins v-erbB; Quinazolines; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome | 2015 |
[Bufalin reverses hepatocyte growth factor-induced resistance to afatinib in H1975 lung cancer cells].
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bufanolides; Cadherins; Cell Line, Tumor; Cell Proliferation; Coloring Agents; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Hepatocyte Growth Factor; Humans; Lung Neoplasms; MAP Kinase Signaling System; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Quinazolines; Signal Transduction; Tetrazolium Salts; Thiazoles | 2015 |
Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series.
Topics: Adenocarcinoma; Afatinib; Brain Neoplasms; Diagnostic Imaging; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.
Topics: Afatinib; Calibration; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Erlotinib Hydrochloride; Gefitinib; Humans; Limit of Detection; Lung Neoplasms; Quinazolines; Tandem Mass Spectrometry | 2016 |
Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.
Topics: Afatinib; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Genes, erbB-2; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Transfection; Xenograft Model Antitumor Assays | 2016 |
HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.
Topics: Afatinib; Antineoplastic Agents; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
[Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Retrospective Studies; Russia; Treatment Outcome | 2015 |
Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
Topics: Afatinib; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines | 2016 |
Small Molecule T315 Promotes Casitas B-Lineage Lymphoma-Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Enzyme Assays; ErbB Receptors; Humans; Lung Neoplasms; Mass Spectrometry; Mice; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Quinazolines; Real-Time Polymerase Chain Reaction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Better treatments needed for breast cancer brain metastases.
Topics: Afatinib; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Female; Humans; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Vinblastine; Vinorelbine | 2015 |
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; ErbB Receptors; Europe; Female; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2016 |
Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Gemcitabine; Gene Deletion; Genetic Markers; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Pemetrexed; Prognosis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Taxoids | 2016 |
Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.
Topics: Acneiform Eruptions; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Compassionate Use Trials; Cross-Sectional Studies; Drug Eruptions; Erlotinib Hydrochloride; Gefitinib; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Pruritus; Quinazolines; Retrospective Studies | 2016 |
Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.
Topics: Adenocarcinoma; Afatinib; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Pancreatic Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Signal Transduction | 2016 |
Effects of cetuximab combined with afatinib on the expression of KDR and AQP1 in lung cancer.
Topics: Afatinib; Antineoplastic Agents; Aquaporin 1; Cell Line, Tumor; Cetuximab; Drug Synergism; Humans; Lung Neoplasms; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
A highly efficient and sensitive LC-MS/MS method for the determination of afatinib in human plasma: application to a metabolic stability study.
Topics: Afatinib; Animals; Calibration; Chromatography, Liquid; Humans; Limit of Detection; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Reference Standards; Reproducibility of Results; Tandem Mass Spectrometry | 2016 |
Afatinib and chemotherapy in non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Humans; Lung Neoplasms; Paclitaxel; Quinazolines | 2016 |
HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK.
Topics: Afatinib; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Inhibitory Concentration 50; JNK Mitogen-Activated Protein Kinases; Lapatinib; MAP Kinase Signaling System; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Quinazolines; STAT5 Transcription Factor | 2016 |
A Spectroscopic Approach to Investigate the Molecular Interactions between the Newly Approved Irreversible ErbB blocker "Afatinib" and Bovine Serum Albumin.
Topics: Afatinib; Animals; Binding Sites; Cattle; Light; Models, Molecular; Oncogene Proteins v-erbB; Protein Binding; Protein Conformation; Protein-Tyrosine Kinases; Quinazolines; Serum Albumin, Bovine; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Static Electricity; Temperature; Thermodynamics | 2016 |
Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Crizotinib; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Maintenance Chemotherapy; Pemetrexed; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Singapore; Taxoids; Translocation, Genetic | 2015 |
Inhibition of proliferation and induction of apoptosis in RB116 retinoblastoma cells by afatinib treatment.
Topics: Afatinib; Animals; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Female; Humans; Mice; Mice, Nude; Quinazolines; Retinoblastoma; Tumor Burden | 2016 |
Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition.
Topics: Afatinib; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Crizotinib; Cyclic S-Oxides; Deoxycytidine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Ligands; MAP Kinase Signaling System; Mutation; Pancreatic Neoplasms; Phenotype; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT3 Transcription Factor | 2016 |
Co-treatment of wild-type EGFR head and neck cancer cell lines with afatinib and cisplatin.
Topics: Afatinib; Cell Line, Tumor; Cisplatin; DNA Mutational Analysis; ErbB Receptors; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Protein Domains; Quinazolines; Treatment Outcome | 2016 |
[Successful Treatment of Non-Small Cell Lung Cancer with Afatinib after Gefitinib-Induced Hepatotoxicity].
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Gefitinib; Humans; Liver Diseases; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2016 |
Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction.
Topics: Afatinib; Animals; Chromatography, Liquid; Female; Linear Models; Liquid-Liquid Extraction; Mice; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry | 2016 |
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Signal Transduction | 2016 |
therascreen® EGFR RGQ PCR Kit: A Companion Diagnostic for Afatinib and Gefitinib in Non-Small Cell Lung Cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Reagent Kits, Diagnostic; Sensitivity and Specificity | 2016 |
Design, synthesis, and docking studies of afatinib analogs bearing cinnamamide moiety as potent EGFR inhibitors.
Topics: Afatinib; Cell Line, Tumor; Cinnamates; Dose-Response Relationship, Drug; Drug Design; ErbB Receptors; HeLa Cells; Humans; MCF-7 Cells; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2016 |
Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Dasatinib; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Mice, Nude; Mutation; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-3; RNA Interference; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays | 2016 |
Afatinib Reduces STAT6 Signaling of Host ARPE-19 Cells Infected with Toxoplasma gondii.
Topics: Afatinib; Antiparasitic Agents; Blotting, Western; Cell Line; Enzyme Activation; Fluorescent Antibody Technique; Humans; Janus Kinase 1; Janus Kinase 3; Phosphorylation; Quinazolines; Signal Transduction; STAT6 Transcription Factor; Toxoplasma; Toxoplasmosis | 2016 |
Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Molecular; Molecular Conformation; Molecular Structure; Mutation; Prognosis; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.
Topics: Adenocarcinoma; Afatinib; Aged; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Mutagenesis, Insertional; Neoplasm Staging; Prognosis; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tumor Cells, Cultured | 2016 |
Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Cancer Care Facilities; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Time Factors | 2016 |
Inequalities in lung cancer: a world of EGFR.
Topics: Afatinib; Crown Ethers; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Geography; Global Health; Health Care Costs; Health Equity; Health Services Accessibility; Healthcare Disparities; Humans; Lung Neoplasms; Medical Oncology; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Surveys and Questionnaires; United States | 2016 |
Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2016 |
Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.
Topics: Adrenal Cortex Hormones; Afatinib; Aged; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Skin; Stevens-Johnson Syndrome; Treatment Outcome | 2016 |
Choroidal metastasis as a presenting manifestation of a lung adenocarcinoma with response to afatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Choroid Neoplasms; ErbB Receptors; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Signal Transduction | 2016 |
Development of a novel noncapillary plasma microsampling device for ultra-low volume of blood collection.
Topics: Afatinib; Animals; Blood Specimen Collection; Dogs; Equipment Design; Mice; Miniaturization; Quinazolines; Radiation-Sensitizing Agents; Rats; Sample Size | 2016 |
Afatinib Is Active in Platinum-Refractory ERBB-Mutant Urothelial Carcinoma.
Topics: Afatinib; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Mutation; Platinum; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Treatment Outcome; Urethral Neoplasms | 2016 |
In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms, Experimental; Quinazolines; Structure-Activity Relationship | 2016 |
Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Asian People; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Everolimus; Feasibility Studies; Female; Genetic Predisposition to Disease; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Pilot Projects; Precision Medicine; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Republic of Korea; Sorafenib; Young Adult | 2016 |
A Triple Rare E709K and L833V/H835L EGFR Mutation Responsive to an Irreversible Pan-HER Inhibitor: A Case Report of Lung Adenocarcinoma Treated with Afatinib.
Topics: Adenocarcinoma; Afatinib; Aged; ErbB Receptors; Humans; Lung Neoplasms; Male; Mutation; Prognosis; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2 | 2016 |
Linking the Price of Cancer Drug Treatments to Their Clinical Value.
Topics: Afatinib; Algorithms; Antineoplastic Agents; Bevacizumab; Cost-Benefit Analysis; Drug Costs; Humans; Italy; Neoplasms; Prevalence; Quality of Life; Quinazolines; Survival Analysis; Treatment Outcome | 2016 |
Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
Topics: Afatinib; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Female; Head and Neck Neoplasms; HEK293 Cells; Humans; Mice; Multigene Family; Mutation; NIH 3T3 Cells; Phosphorylation; Quinazolines; Receptor, ErbB-4; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2016 |
Stevens-Johnson syndrome-like erosive dermatitis possibly related to afatinib.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Agents; Drug Eruptions; Female; Humans; Lung Neoplasms; Quinazolines | 2016 |
Evaluation of assays for drug efficacy in a three-dimensional model of the lung.
Topics: Afatinib; Cell Cycle; Cell Proliferation; Cisplatin; Drug Screening Assays, Antitumor; Humans; Lung; Lung Neoplasms; Quinazolines; Spheroids, Cellular; Tissue Culture Techniques; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2016 |
[Not Available].
Topics: Afatinib; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
Molecular Basis for Redox Activation of Epidermal Growth Factor Receptor Kinase.
Topics: Afatinib; Enzyme Activation; ErbB Receptors; Humans; Molecular Dynamics Simulation; Mutation; Oxidation-Reduction; Oxidative Stress; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 2016 |
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain Neoplasms; Caco-2 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Dogs; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Madin Darby Canine Kidney Cells; Male; Mice; Mice, SCID; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Xenograft Model Antitumor Assays | 2016 |
Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases.
Topics: Afatinib; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2016 |
Non-small Cell Lung Cancer in South Wales: Are Exon 19 Deletions and L858R Different?
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Humans; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Wales | 2016 |
Ethacrynic acid improves the antitumor effects of irreversible epidermal growth factor receptor tyrosine kinase inhibitors in breast cancer.
Topics: Afatinib; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Ethacrynic Acid; Female; Humans; MAP Kinase Signaling System; MCF-7 Cells; Mice, Inbred BALB C; Protein Kinase Inhibitors; Quinazolines; Quinolines; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2016 |
Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer with Acquired Resistance.
Topics: Afatinib; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Prognosis; Quinazolines; Radiation-Sensitizing Agents | 2016 |
Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Middle Aged; Mutation; Pilot Projects; Prospective Studies; Quinazolines; Radiation-Sensitizing Agents | 2016 |
Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Biopsy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma.
Topics: Administration, Oral; Adult; Afatinib; Aged; Aged, 80 and over; Calibration; Carbamates; Chromatography, Liquid; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Reproducibility of Results; Sulfonamides; Tandem Mass Spectrometry | 2016 |
Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer.
Topics: Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Ligands; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sulfones; Translocation, Genetic | 2017 |
Afatinib-Induced Severe Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy: A Case Report.
Topics: Adrenal Cortex Hormones; Afatinib; Aged, 80 and over; Humans; Lung Diseases, Interstitial; Male; Quinazolines | 2017 |
Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Male; Mutation; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiation-Sensitizing Agents; Treatment Outcome | 2016 |
Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antigens, Neoplasm; B7-H1 Antigen; Biomarkers, Tumor; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; ErbB Receptors; Galectins; Humans; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Quinazolines; Receptor, ErbB-2; Survival Analysis | 2016 |
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epiderm
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Costs; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation.
Topics: Afatinib; Antineoplastic Agents; Cell Culture Techniques; Cells, Cultured; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Protein Kinase Inhibitors; Quinazolines; Transfection | 2017 |
Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Quinazolines; Remission Induction; Tomography, X-Ray Computed; Withholding Treatment | 2017 |
Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Body Surface Area; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Feasibility Studies; Female; Gene Expression Regulation; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Radiation-Sensitizing Agents; Retrospective Studies | 2016 |
Tolerability and efficacy of afatinib at a low starting dosage in 10 elderly or low performance status patients with advanced refractory non-small-cell lung cancer.
Topics: Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; ErbB Receptors; Female; Humans; Intra-Abdominal Fat; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiation-Sensitizing Agents; Retrospective Studies; Salvage Therapy; Survival Rate | 2016 |
Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Renal Dialysis | 2017 |
Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Doxorubicin; Epidermal Growth Factor; ErbB Receptors; Female; Humans; Mice; Mice, Nude; Neuroblastoma; Quinazolines; Radiation-Sensitizing Agents; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.
Topics: Adult; Afatinib; Aged; Amino Acid Sequence; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Conformation; Protein Domains; Protein Multimerization; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Retrospective Studies; Sequence Alignment | 2017 |
Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.
Topics: Afatinib; Alleles; Amino Acid Substitution; Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Codon; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mice; Models, Molecular; Molecular Conformation; Mutagenesis; Mutation; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Structure-Activity Relationship | 2017 |
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR-mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Quinazolines; Radiation-Sensitizing Agents | 2017 |
Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gene Rearrangement; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Survival Rate | 2017 |
An autopsy case of bronchiolitis obliterans as a previously unrecognized adverse event of afatinib treatment.
Topics: Adenocarcinoma; Afatinib; Autopsy; Bronchiolitis Obliterans; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2017 |
Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis.
Topics: Adult; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Treatment Outcome | 2017 |
EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
Topics: Acrylamides; Adenocarcinoma; Afatinib; Alleles; Aniline Compounds; Animals; Antineoplastic Agents; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Middle Aged; NIH 3T3 Cells; Phosphorylation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2017 |
Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Circulating Tumor DNA; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Profiling; Genome; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Neoplasm Metastasis; Oncogene Proteins, Fusion; Quinazolines; Receptor, Fibroblast Growth Factor, Type 3; Recurrence | 2017 |
Novel EGFR Exon 18 (G721R) Mutation in a Patient with Non-Small Cell Lung Carcinoma with Lack of Response to Afatinib.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2017 |
An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Quinazolines | 2017 |
Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4.
Topics: Afatinib; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cytochrome P-450 CYP3A; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab; Up-Regulation | 2017 |
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Topics: Adenocarcinoma; Ado-Trastuzumab Emtansine; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Dosage; Genes, erbB-2; Humans; Lung Neoplasms; Male; Maytansine; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Quinazolines; Retrospective Studies; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2017 |
Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Circulating Tumor DNA; ErbB Receptors; Female; High-Throughput Nucleotide Sequencing; Humans; Liquid Biopsy; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prospective Studies; Quinazolines | 2017 |
Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.
Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cohort Studies; Extracellular Space; Female; Fluorescent Antibody Technique; Humans; Intracellular Space; Lapatinib; Maytansine; Middle Aged; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Protein Domains; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Tissue Array Analysis; Trastuzumab; Uterine Neoplasms | 2017 |
[Precision first-line therapy for advanced non-small-cell lung cancer patients harboring EGFR mutation].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Afatinib ameliorates osteoclast differentiation and function through downregulation of RANK signaling pathways.
Topics: Afatinib; Animals; Bone Marrow Cells; Bone Resorption; Cell Differentiation; Down-Regulation; ErbB Receptors; JNK Mitogen-Activated Protein Kinases; Macrophages; Mice; NF-kappa B; Osteoclasts; Phosphorylation; Quinazolines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction | 2017 |
Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Topics: Afatinib; Agranulocytosis; Blast Crisis; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Genes, erbB-1; Humans; Leukemia, Myelomonocytic, Chronic; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
An Acquired
Topics: Afatinib; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2 | 2017 |
Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Complete Tumor Response with Afatinib 20 mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Biomarkers, Tumor; Cell Line, Tumor; Cluster Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Isotope Labeling; Lung Neoplasms; Mass Spectrometry; Mutation; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Proteomics; Quinazolines; Reproducibility of Results; Signal Transduction; Tyrosine | 2017 |
Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.
Topics: Adenocarcinoma; Afatinib; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Remission Induction; Xenograft Model Antitumor Assays | 2017 |
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hedgehog Proteins; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells.
Topics: Afatinib; Animals; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Proliferation; ErbB Receptors; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Gene Fusion; Humans; Lung Neoplasms; Male; Middle Aged; Neuregulin-1; Quinazolines | 2017 |
Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC).
Topics: Afatinib; Amides; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Models, Biological; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Thiophenes | 2017 |
Improved oral bioavailability and brain accumulation of afatinib due to dual inhibition of the efflux mechanisms of BCRP and Pgp transporters -What next?
Topics: Administration, Oral; Afatinib; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Availability; Brain; Humans; Neoplasm Proteins; Quinazolines; Radiation-Sensitizing Agents | 2017 |
Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Filaggrin Proteins; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines | 2017 |
Antibiofilm activity and mode of action of DMSO alone and its combination with afatinib against Gram-negative pathogens.
Topics: Afatinib; Anti-Bacterial Agents; Biofilms; Dimethyl Sulfoxide; Drug Synergism; Escherichia coli; Pseudomonas aeruginosa; Quinazolines; Salmonella typhimurium; Spectroscopy, Fourier Transform Infrared | 2018 |
What next? Preferably development of drugs that are no longer transported by the ABCB1 and ABCG2 efflux transporters.
Topics: Afatinib; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Transport; Drug Discovery; Humans; Quinazolines | 2017 |
Afatinib Decreases P-Glycoprotein Expression to Promote Adriamycin Toxicity of A549T Cells.
Topics: A549 Cells; Afatinib; ATP Binding Cassette Transporter, Subfamily B; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Proteins; Quinazolines | 2018 |
Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; ErbB Receptors; Exons; Female; Humans; INDEL Mutation; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2017 |
HER2 regulates cancer stem-like cell phenotype in ALK translocated NSCLC.
Topics: Afatinib; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Neoplastic Stem Cells; Neuregulin-1; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Translocation, Genetic | 2017 |
Matrine increases the inhibitory effects of afatinib on H1975 cells via the IL‑6/JAK1/STAT3 signaling pathway.
Topics: Afatinib; Alkaloids; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Humans; Interleukin-6; Janus Kinase 1; Lung Neoplasms; Matrines; Protein Kinase Inhibitors; Quinazolines; Quinolizines; Signal Transduction; STAT3 Transcription Factor | 2017 |
Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome | 2017 |
The Effect of Afatinib Treatment in Non-small Cell Lung Cancer Cells.
Topics: A549 Cells; Afatinib; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Heat-Shock Proteins; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Signal Transduction | 2017 |
Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
Case series on the association between blood levels and side effects of afatinib maleate.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Quinazolines | 2017 |
Significance of neutrophil-to-lymphocyte ratio in Western advanced EGFR-mutated non-small cell lung cancer receiving a targeted therapy.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Neutrophils; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2017 |
Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
Topics: Afatinib; Antineoplastic Agents; Cell Line, Tumor; Cytotoxicity, Immunologic; Drug Interactions; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; L-Lactate Dehydrogenase; Lapatinib; MCF-7 Cells; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2017 |
Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents | 2017 |
Treatment with a programmed cell death-1-specific antibody has little effect on afatinib- and naphthalene-induced acute pneumonitis in mice.
Topics: Acute Disease; Afatinib; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Mice, Inbred C57BL; Naphthalenes; Pneumonia; Programmed Cell Death 1 Receptor; Quinazolines; Treatment Outcome | 2017 |
YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells.
Topics: Afatinib; Antineoplastic Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; ErbB Receptors; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Imidazoles; Lung Neoplasms; Methylation; Naphthoquinones; Octamer Transcription Factor-3; Phosphorylation; Quinazolines; RNA, Messenger | 2017 |
[A Case of Lung Adenocarcinoma Presenting with Leptomeningeal Carcinomatosis Successfully Treated with Afatinib after Erlotinib-Induced Hepatotoxicity].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Quinazolines; Treatment Outcome | 2017 |
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
Topics: ADAMTS Proteins; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium-Binding Proteins; Calponins; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exome; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Lung Neoplasms; Male; Microfilament Proteins; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53; Wnt Proteins | 2017 |
Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydrogen-Ion Concentration; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Urine | 2017 |
Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Medical Oncology; Neoplasm Metastasis; Nivolumab; Quinazolines; Ramucirumab; Taxoids | 2017 |
Cx32 inhibits TNFα-induced extrinsic apoptosis with and without EGFR suppression.
Topics: Afatinib; Apoptosis; Connexins; Cycloheximide; Doxycycline; ErbB Receptors; Female; Gap Junction beta-1 Protein; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Inhibitor of Apoptosis Proteins; Phosphorylation; Quinazolines; Survivin; Tumor Necrosis Factor-alpha; Uterine Cervical Neoplasms | 2017 |
Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged, 80 and over; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines | 2017 |
Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Bile Duct Neoplasms; Cholangiocarcinoma; Female; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Neuregulin-1; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Quinazolines; Syndecan-4 | 2017 |
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Imidazoles; Lung Neoplasms; Male; Mice; Mice, Nude; Pemetrexed; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Random Allocation; Triazines; Xenograft Model Antitumor Assays | 2017 |
Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab.
Topics: Afatinib; Aged; Antibodies, Monoclonal; Carcinoma, Squamous Cell; Disease Progression; Humans; Lung Neoplasms; Male; Nivolumab; Quinazolines | 2018 |
Inhibitory Effect of Afatinib on Platelet Activation and Apoptosis.
Topics: Afatinib; Animals; Apoptosis; Blood Platelets; Calcium; Carrier Proteins; Caspase 3; Cell Size; Female; Male; Mice; ORAI1 Protein; P-Selectin; Peptides; Platelet Activation; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Quinazolines; Thrombin | 2017 |
Suppressors for Human Epidermal Growth Factor Receptor 2/4 (HER2/4): A New Family of Anti-Toxoplasmic Agents in ARPE-19 Cells.
Topics: Afatinib; Aminoquinolines; Aniline Compounds; Animals; Cell Line; Gefitinib; Humans; Mice, Inbred BALB C; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Quinolines; Receptor, ErbB-2; Toxoplasma; Tyrphostins | 2017 |
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers.
Topics: Adrenergic beta-Antagonists; Afatinib; AMP-Activated Protein Kinase Kinases; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclic AMP Response Element-Binding Protein; Drug Resistance, Neoplasm; Epinephrine; ErbB Receptors; Humans; Interleukin-6; Lung Neoplasms; Mutation; Norepinephrine; Protein Kinase C; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Receptors, Adrenergic, beta; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2017 |
A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Female; Humans; Lung Neoplasms; Middle Aged; Neuregulin-1; Quinazolines; Radiation-Sensitizing Agents | 2017 |
Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2018 |
Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Exons; Female; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Sequence Analysis, DNA; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome | 2018 |
The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2017 |
Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Diagnostic Techniques; Netherlands; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2018 |
A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2018 |
Development of a method to determine axitinib, lapatinib and afatinib in plasma by micellar liquid chromatography and validation by the European Medicines Agency guidelines.
Topics: Afatinib; Antineoplastic Agents; Axitinib; Chromatography, Liquid; Drug Stability; Humans; Imidazoles; Indazoles; Lapatinib; Limit of Detection; Linear Models; Micelles; Neoplasms; Quinazolines; Reproducibility of Results | 2018 |
Investigation of the binding characteristics between ligands and epidermal growth factor receptor by cell membrane chromatography.
Topics: Afatinib; Cell Membrane; Chromatography; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HEK293 Cells; Humans; Ligands; Molecular Docking Simulation; Morpholines; Piperidines; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2018 |
Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Selection; Program Evaluation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Failure | 2018 |
[Analysis of Time-to-onset of Interstitial Lung Disease after the Administration of Small Molecule Molecularly-targeted Drugs].
Topics: Adverse Drug Reaction Reporting Systems; Afatinib; Bortezomib; Carbazoles; Cluster Analysis; Crizotinib; Dasatinib; Databases as Topic; Datasets as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Japan; Lung Diseases, Interstitial; Molecular Targeted Therapy; Particle Size; Piperidines; Pyrazoles; Pyridines; Quinazolines; Time Factors | 2018 |
The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome | 2018 |
P-gp is involved in the intestinal absorption and biliary excretion of afatinib in vitro and in rats.
Topics: Adenosine Triphosphatases; Afatinib; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Biological Transport; Caco-2 Cells; Cell Line, Tumor; Cyclosporine; Hepatobiliary Elimination; Hepatocytes; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Male; Quinazolines; Rats; Rats, Wistar; Verapamil | 2018 |
Skin Rash Can Be a Useful Marker for Afatinib Efficacy.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Stomatitis; Treatment Outcome | 2018 |
Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Quinazolines; Radiation-Sensitizing Agents | 2018 |
Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Exons; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Quinazolines; Survival Analysis; Time Factors | 2018 |
Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; Lung Neoplasms; Mice; Neoplastic Stem Cells; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Taxoids; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cardiotonic Agents; Cardiovascular Diseases; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Nebivolol; Piperazines; Protein Kinase Inhibitors; Quinazolines; Ramipril | 2018 |
Comparative studies on the human serum albumin binding of the clinically approved EGFR inhibitors gefitinib, erlotinib, afatinib, osimertinib and the investigational inhibitor KP2187.
Topics: Acrylamides; Afatinib; Aniline Compounds; Binding Sites; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hydrogen Bonding; Molecular Docking Simulation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Serum Albumin, Human; Solvents; Spectrometry, Fluorescence | 2018 |
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Topics: Afatinib; Animals; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mice; Mutagenesis, Insertional; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Tumor Burden | 2018 |
Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan.
Topics: Adult; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Budgets; Carcinoma, Non-Small-Cell Lung; Decision Making, Organizational; Disease-Free Survival; ErbB Receptors; Exons; Health Planning; Humans; Lung Neoplasms; Models, Biological; Models, Economic; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; United States; Young Adult | 2018 |
CRISPR/Cas9 Genome Editing of Epidermal Growth Factor Receptor Sufficiently Abolished Oncogenicity in Anaplastic Thyroid Cancer.
Topics: Afatinib; Antineoplastic Agents; Cell Cycle; Cell Death; Cell Line, Tumor; CRISPR-Cas Systems; ErbB Receptors; Gene Editing; Humans; Protein Kinase Inhibitors; Quinazolines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2018 |
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung canc
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Crizotinib; Drug Monitoring; Drug Stability; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Limit of Detection; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2018 |
Stimulation of Eryptosis by Afatinib.
Topics: Afatinib; Anemia; Calcium Signaling; Eryptosis; Erythrocyte Membrane; Humans; Phospholipids; Quinazolines | 2018 |
[The efficacy of TKIs in treatment of human primary small cell lung cancer xenograft model in vivo].
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib.
Topics: Afatinib; Aged; Algorithms; Antineoplastic Agents; Canada; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies | 2019 |
Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Databases, Factual; ErbB Receptors; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2018 |
[Formulation and Efficacy of Liposome-encapsulated Afatinib for Therapy of Non-small Cell Lung Cancer].
Topics: Afatinib; Capsules; Carcinoma, Non-Small-Cell Lung; Drug Compounding; Liposomes; Lung Neoplasms; Quinazolines | 2018 |
Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay.
Topics: Adult; Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Male; Mutation; Precision Medicine; Quinazolines; Treatment Outcome | 2018 |
An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Proteomics; Quinazolines; Research Design | 2018 |
Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib.
Topics: Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Mutagenesis, Insertional; Quinazolines; Sequence Deletion | 2019 |
Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Topics: Afatinib; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Sulfonamides | 2019 |
Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
Topics: Adenocarcinoma of Lung; Afatinib; Aged; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
Topics: Acrylamides; Afatinib; Aged; Aniline Compounds; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Fatal Outcome; Female; Follow-Up Studies; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines | 2019 |
Survival analysis of afatinib versus erlotinib for individuals with advanced del19 lung adenocarcinoma with asymptomatic brain metastasis after pemetrexed-cisplatin chemotherapy: a retrospective study.
Topics: Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Pemetrexed; Quinazolines; Retrospective Studies; Survival Analysis | 2020 |
Long-term response to second-line afatinib treatment for advanced squamous cell carcinoma non-small cell lung cancer: a rare case report.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2020 |
HER2 amplification as a potential mechanism of acquired resistance to afatinib in an advanced non-small-cell lung cancer patient.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2021 |
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.
Topics: Afatinib; Allosteric Regulation; Binding Sites; Catalytic Domain; Colorectal Neoplasms; ErbB Receptors; Humans; Molecular Dynamics Simulation; Mutagenesis, Site-Directed; Protein Interaction Maps; Proto-Oncogene Proteins p21(ras); Quinazolines; SOS1 Protein | 2021 |
Differential effects of epidermal growth factor receptor inhibitors in a single patient with neuropathic pain.
Topics: Afatinib; ErbB Receptors; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neuralgia; Protein Kinase Inhibitors; Quinazolines | 2021 |
Combination treatment with bevacizumab plus erlotinib for meningeal carcinomatosis of afatinib-resistant EGFR mutated lung cancer without T790M mutation: a case report.
Topics: Afatinib; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Successful erlotinib rechallenge in an EGFR-mutant metastatic non-small cell lung cancer patient with afatinib-induced drug rash with eosinophilia and systemic symptoms: A case report.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Eosinophilia; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Crown Ethers; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry | 2022 |
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2023 |
A case of crescentic glomerulonephritis induced by afatinib for lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; ErbB Receptors; Glomerulonephritis; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Renal Dialysis | 2023 |
Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study.
Topics: Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2023 |
Non-small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib.
Topics: Afatinib; Aged; beta Catenin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |